



(51) International Patent Classification:

C07K 7/06 (2006.01) A61K 38/08 (2006.01)
C07K 7/08 (2006.01) A61K 38/10 (2006.01)
C12N 15/12 (2006.01) A61P 35/00 (2006.01)
C12N 5/10 (2006.01)

(21) International Application Number:

PCT/US2012/064511

(22) International Filing Date:

9 November 2012 (09.11.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/558,953 11 November 2011 (11.11.2011) US

(71) Applicant: FRED HUTCHINSON CANCER RESEARCH CENTER [US/US]; 1100 Fairview Avenue North, J5-110, Seattle, Washington 98109 (US).

(72) Inventors: GREENBERG, Philip; 6510 82nd Avenue Southeast, Mercer Island, Washington 98040 (US). OCHSENREITHER, Sebastian; Elastr. 5, 12159 Berlin (DE).

(74) Agents: ROSENMAN, Stephen, J. et al.; Seed Intellectual Property Law Group PLLC, Suite 5400, 701 Fifth Avenue, Seattle, Washington 98104-7064 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

[Continued on next page]

(54) Title: CYCLIN A1-TARGETED T-CELL IMMUNOTHERAPY FOR CANCER




Fig. 6

(57) Abstract: Compositions and methods are provided for eliciting antigen-specific T-cell responses against human cyclin A1 (CCNA1), which is herein identified as a leukemia-associated antigen based on its overexpression in acute myeloid leukemia (AML) including leukemia stem cells (LSC) and in immunologically privileged testis cells, but not in other normal cell types. CCNA1-derived peptide epitopes that are immunogenic for T-cells including CTL are disclosed, as are immunotherapeutic approaches using such peptides for vaccines and generation of adoptive transfer therapeutic cells.





TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). **Published:**

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

CYCLIN A1-TARGETED T-CELL IMMUNOTHERAPY FOR CANCER

STATEMENT OF GOVERNMENT INTEREST

This invention was made with government support under Grant No. P01 CA018029 awarded by the National Institutes of Health/ National
5 Cancer Institute. The government has certain rights in this invention.

STATEMENT REGARDING SEQUENCE LISTING

The Sequence Listing associated with this application is provided in text format in lieu of a paper copy, and is hereby incorporated by reference
10 into the specification. The name of the text file containing the Sequence Listing 360056_407WO_SEQUENCE_LISTING.txt. The text file is about 9 KB, was created on November 9, 2012, and is being submitted electronically via EFS-Web.

BACKGROUND

15 Technical Field

The present disclosure relates generally to methods for eliciting antigen-specific T-cell immune responses to a cancer-associated antigen. More specifically, the human cyclin A1 (CCNA1) isoform c polypeptide is herein identified as containing epitopes useful for the elicitation of specific T-cell
20 responses against leukemic cells that overexpress CCNA1, including leukemic stem cells (LSC) and acute myeloid leukemia (AML) cells.

Description of the Related Art

In higher vertebrates the immune system distinguishes “self” from “non-self” molecular structures in cells and tissues, and provides a host
25 organism with the means to quickly and specifically mount protective responses, such as destruction of pathogenic microorganisms and rejection of malignant tumors. Immune responses have been generally described as

including humoral responses, in which antibodies specific for antigens are produced by differentiated B lymphocytes, and cell-mediated responses, in which various types of T lymphocytes eliminate antigens by a variety of mechanisms. For example, CD4 (also called CD4+) helper T-cells that are
5 capable of recognizing specific antigens may respond by releasing soluble mediators such as cytokines to recruit additional cells of the immune system to participate in an immune response by a variety of mechanisms. CD8 (also called CD8+) cytotoxic T lymphocytes (CTL) are also capable of recognizing specific antigens and may bind to, and destroy or damage, an antigen-bearing
10 cell or particle. In particular, cell mediated immune responses that include a cytotoxic T lymphocyte (CTL) response can be important for elimination of tumor cells and also for elimination of cells infected by pathogens, such as viruses, bacteria, or microbial parasites.

It is well established that acute myeloid leukemia (AML) is
15 organized hierarchically, initiated and maintained by a small population of cells referred to as leukemia stem cells (LSCs) that are characterized not only by unlimited reproductive capacity but also by enhanced resistance to chemotherapy and radiation. This primitive cell population, which has been found to be negative for the expression of lineage markers and CD38 but
20 positive for CD34, is essential for long-term engraftment of primary AML cells in NOD/SCID transplantation models (Bonnet et al., 1997 *Nat Med* 3 (7):730-737; Lapidot et al., 1994 *Nature* 367 (6464):645-648. doi:10.1038/367645a0; Blair et al., 1998 *Blood* 92 (11):4325-4335). The leukemia stem cell hypothesis suggests that for a therapeutic anti-AML effect to be curative in patients,
25 beneficial strategies would include those that efficiently eliminate the LSC compartment, which is resistant to conventional therapy approaches.

In patients with intermediate- and high-risk and/or relapsed AML, the allogeneic T-cell mediated graft-versus-leukemia effect detected in some individuals following hematopoietic stem cell transplantation (HSCT) or after
30 infusion of donor-derived lymphocytes in the post-transplant period has been shown to be essential for the achievement of long-term complete remissions

(Cornelissen et al., 2007 *Blood* 109 (9):3658-3666. doi:blood-2006-06- 025627 [pii] 10.1182/ blood-2006-06-025627; Yanada et al., 2005 *Cancer* 103 (8):1652-1658. doi:10.1002/ cncr.20945; Breems et al., 2005 *J Clin Oncol* 23 (9):1969-1978. doi:JCO. 2005.06.027 [pii] 10.1200/ JCO.2005.06.027; Levine et al., 2002 *J Clin Oncol* 20 (2):405-412). However, allogeneic HSCT and unselected donor lymphocyte infusions are associated with significant toxicity due to both the conditioning regimen and the graft versus-host activity of donor lymphocytes. An alternative strategy for providing an anti-LSC cytotoxic T-lymphocyte (CTL) component to the treatment of AML patients would be to engage more targeted T-cell therapy, consisting of either the adoptive transfer of T-cells specific for, or the vaccination against, leukemia associated antigens (LAA) (Van Driessche et al., 2005 *Leukemia* 19 (11):1863-1871. doi: 2403930 [pii] 10.1038/ sj.leu.2403930; Rezvani et al., 2008 *Blood* 111 (1):236-242. doi: blood-2007- 08-108241 [pii] 10.1182/ blood-2007-08-108241). The ability of antigen-specific T-cells to mediate elimination of AML LSCs has already been demonstrated in NOD/SCID transplantation models (Bonnet et al., 1999 *Proc Natl Acad Sci USA* 96 (15):8639-8644; Rosinski et al., 2008 *Blood* 111 (9):4817-4826. doi:blood -2007-06- 096313 [pii] 10.1182/ blood-2007-06-096313; Xue et al., 2005 *Blood* 106 (9):3062-3067. doi:2005-01-0146 [pii] 10.1182/ blood-2005-01-0146).

Targeted T-cell therapy represents a potentially less toxic strategy than allogeneic hematopoietic stem cell transplantation to provide a cytotoxic anti-leukemia effect for eliminating the leukemic stem cell (LSC) compartment in acute myeloid leukemia (AML) patients. However, this strategy requires the identification of leukemia-associated antigens (LAA) that exhibit selective high expression in AML LSCs to maximize the anti-leukemic effect and minimize immune-mediated toxicities in normal tissues.

A precondition for targeted T-cell therapy achieving a maximal anti-AML effect that would be accompanied by minimal immunological toxicity is therefore to identify LAAs with high expression in and presentation by the malignant cell compartment, but without significant expression in healthy

tissues. Although several AML LAAs have been described, only Wilms tumor protein 1 (WT1) has been shown to be expressed in the LSC compartment of the majority of AML patients at levels significantly higher than in physiological hematopoietic stem cells (HSCs). WT1 is currently being targeted in clinical
5 trials both with adoptive T-cell transfer and peptide vaccination (e.g., U.S. Pat. Nos. 7,342,092; 7,608,685; 7,622,119), and objective remissions have been observed in some patients (Cheever et al., 2009 *Clin Cancer Res* 15 (17):5323-5337. doi:15/17/ 5323 [pii] 10.1158/ 1078-0432.CCR -09-0737; Majeti et al., 2009 *Proc Natl Acad Sci USA* 106 (9): 3396-3401. doi: 0900089106 [pii]
10 10.1073/ pnas.0900089106; Xue et al., 2005 *Blood* 106 (9):3062-3067; Keilholz et al., 2009 *Blood* 113 (26):6541-6548. doi:blood- 2009-02-202598 [pii] 10.1182/ blood-2009-02- 202598). In some AML patients, however, WT1 is not expressed, or is not detected at levels sufficiently distinct from those in HSC, or no anti-WT1 T-cell response can be elicited. WT1 expression has also been
15 detected in several non-hematopoietic organs such as spleen, ovary and kidney, at levels that can be as high or higher than in leukemic blasts, raising concerns that WT1-targeted immunotherapy would produce toxicities in these tissues as undesirable and potentially harmful side-effects.

Clearly there is a need for additional candidate leukemia-
20 associated antigens that are expressed in malignant cells including AML cells, and in particular in AML leukemic stem cells, to be used as immunogens for the development of highly specific, targeted immunotherapies for the treatment of cancers, including leukemias such as AML. The presently disclosed invention embodiments address this need and provide other related advantages.

25

BRIEF SUMMARY

The present invention provides, according to certain
embodiments, an isolated peptide capable of eliciting an antigen-specific T-cell
response to human cyclin A1 (CCNA1), comprising a polypeptide of no more
30 than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8 or 7 amino acids wherein the

polypeptide comprises a sequence of at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 contiguous amino acids from the CCNA1 amino acid sequence set forth in SEQ ID NO:9.

In another embodiment there is provided an isolated peptide
5 capable of eliciting an antigen-specific T-cell response to human cyclin A1 (CCNA1), comprising a polypeptide of general formula I: N-X-C, [I] wherein: (a) N-X-C is a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10 or 9 amino acids in which X comprises an amino acid sequence that is selected from: CCNA1(120-131) VDTGTLKSDLHF [SEQ ID NO:1],
10 CCNA1(218-226) AETLYLAVN [SEQ ID NO:2], CCNA1(227-235) FLDRFLSCM [SEQ ID NO:3], CCNA1(253-261) ASKYEEIYP [SEQ ID NO:4], CCNA1(118-127) YEVDGTLKS [SEQ ID NO:5], CCNA1(167-175) YAEIYQYL [SEQ ID NO:6], CCNA1(330-339) LEADPFLKYL [SEQ ID NO:7], and CCNA1(341-351) SLIAAAAFCLA [SEQ IN NO:8], (b) N is an amino
15 terminus of the peptide and consists of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino acids that are independently selected from natural amino acids and non-natural amino acids, and (c) C is a carboxy terminus of the peptide and consists of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino acids that are independently selected from natural amino acids and non-natural amino acids.

20 In certain further embodiments the antigen-specific T-cell response comprises major histocompatibility complex (MHC)-restricted T-cell recognition of the peptide. In certain other further embodiments the isolated peptide is capable of eliciting an antigen-specific CD8⁺ T-cell response to human cyclin A1 (CCNA1) in a class I human leukocyte antigen (HLA)-
25 restricted manner. In a still further embodiment the class I HLA antigen is HLA-A*201. In certain other further embodiments the isolated peptide is capable of eliciting an antigen-specific CD4⁺ T-cell response to human cyclin A1 (CCNA1) in a class II human leukocyte antigen (HLA)-restricted manner. In certain other further embodiments the antigen-specific T-cell response comprises an
30 interferon-gamma (IFN- γ) response. In certain other further embodiments the antigen-specific T-cell response comprises at least one of a CD4⁺ helper T

lymphocyte (Th) response and a CD8+ cytotoxic T lymphocyte (CTL) response. In certain further embodiments the CTL response is directed against a CCNA1-overexpressing cell. In certain still further embodiments the CCNA1-overexpressing cell is an acute myeloid leukemia (AML) cell or a leukemic stem
5 cell (LSC).

Turning to another embodiment, there is provided an isolated polynucleotide that encodes a peptide that is capable of eliciting an antigen-specific T-cell response to human cyclin A1 (CCNA1), the peptide comprising a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8 or 7
10 amino acids wherein the polypeptide comprises a sequence of at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 contiguous amino acids from the CCNA1 amino acid sequence set forth in SEQ ID NO:9.

In another embodiment there is provided an isolated polynucleotide that encodes a peptide that is capable of eliciting an antigen-
15 specific T-cell response to human cyclin A1 (CCNA1), the peptide comprising a polypeptide of general formula I: N-X-C, [I] wherein: (a) N-X-C is a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10 or 9 amino acids in which X comprises an amino acid sequence that is selected from the group consisting of: CCNA1(120-131) VDTGTLKSDLHF [SEQ ID NO:1],
20 CCNA1(218-226) AETLYLAVN [SEQ ID NO:2], CCNA1(227-235) FLDRFLSCM [SEQ ID NO:3], CCNA1(253-261) ASKYEEIYP [SEQ ID NO:4], CCNA1(118-127) YEVDGTLKS [SEQ ID NO:5], CCNA1(167-175) YAEIYQYL [SEQ ID NO:6], CCNA1(330-339) LEADPFLKYL [SEQ ID NO:7], and CCNA1(341-351) SLIAAAAFCLA [SEQ IN NO:8], (b) N is an amino
25 terminus of the peptide and consists of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino acids that are independently selected from natural amino acids and non-natural amino acids, and (c) C is a carboxy terminus of the peptide and consists of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino acids that are independently selected from natural amino acids and non-natural amino acids.

30 In certain other embodiments there is provided an immunogenic composition comprising a recombinant expression vector comprising either of

the polynucleotides just described operably linked to an expression control sequence. In a further embodiment the vector is capable of delivering the polynucleotide to an antigen-presenting cell. In a still further embodiment the antigen-presenting cell is a dendritic cell. In certain other further embodiments the antigen-specific T-cell response comprises major histocompatibility complex (MHC)-restricted T-cell recognition of the peptide. In certain other further 5 embodiments the immunogenic composition is capable of eliciting an antigen-specific CD8⁺ T-cell response to human cyclin A1 (CCNA1) in a class I human leukocyte antigen (HLA)-restricted manner. In a still further embodiment the class I HLA antigen is HLA-A*201. In certain other further embodiments the immunogenic composition is capable of eliciting an antigen-specific CD4⁺ T-cell response to human cyclin A1 (CCNA1) in a class II human leukocyte antigen (HLA)-restricted manner. In certain other further embodiments the antigen-specific T-cell response comprises an interferon-gamma (IFN- γ) response. In 15 certain other further embodiments the antigen-specific T-cell response comprises at least one of a CD4⁺ helper T lymphocyte (Th) response and a CD8⁺ cytotoxic T lymphocyte (CTL) response. In certain further embodiments the CTL response is directed against a CCNA1-overexpressing cell, which in certain still further embodiments is an acute myeloid leukemia (AML) cell or a leukemic stem cell (LSC). 20

According to certain other embodiments there is provided a method of treating a condition characterized by CCNA1 overexpression in cells of a subject, comprising administering to the subject an effective amount of a composition that comprises one or more isolated peptides that are capable of 25 eliciting an antigen-specific T-cell response to human cyclin A1 (CCNA1), each of said isolated peptides comprising a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8 or 7 amino acids wherein the polypeptide comprises a sequence of at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 contiguous amino acids from the CCNA1 amino acid sequence set forth in 30 SEQ ID NO:9.

In another embodiment there is provided a method of treating a condition characterized by CCNA1 overexpression in cells of a subject, comprising administering to the subject an effective amount of a composition that comprises one or more isolated peptides that are capable of eliciting an antigen-specific T-cell response to human cyclin A1 (CCNA1), each of said

5 isolated peptides comprising a polypeptide of general formula I: N-X-C, [I] wherein: (a) N-X-C is a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10 or 9 amino acids in which X comprises an amino acid sequence that is selected from: CCNA1(120-131) VDTGTLKSDLHF [SEQ ID NO:1],

10 CCNA1(218-226) AETLYLAVN [SEQ ID NO:2], CCNA1(227-235) FLDRFLSCM [SEQ ID NO:3], CCNA1(253-261) ASKYEEIYP [SEQ ID NO:4], CCNA1(118-127) YEVDGTGLKS [SEQ ID NO:5], CCNA1(167-175) YAEIYQYL [SEQ ID NO:6], CCNA1(330-339) LEADPFLKYL [SEQ ID NO:7], and CCNA1(341-351) SLIAAAAFCLA [SEQ IN NO:8], (b) N is an amino

15 terminus of the peptide and consists of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino acids that are independently selected from natural amino acids and non-natural amino acids, and (c) C is a carboxy terminus of the peptide and consists of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino acids that are independently selected from natural amino acids and non-natural amino acids.

20 In another embodiment there is provided a method of treating a condition characterized by CCNA1 overexpression in cells of a subject, comprising administering to the subject an effective amount of a composition that comprises one or more isolated polynucleotides that each encodes a peptide that is capable of eliciting an antigen-specific T-cell response to human

25 cyclin A1 (CCNA1), each of said peptides comprising a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8 or 7 amino acids wherein the polypeptide comprises a sequence of at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 contiguous amino acids from the CCNA1 amino acid sequence set forth in SEQ ID NO:9.

30 In another embodiment there is provided a method of treating a condition characterized by CCNA1 overexpression in cells of a subject,

comprising administering to the subject an effective amount of a composition that comprises one or more isolated polynucleotides that each encodes a peptide that is capable of eliciting an antigen-specific T-cell response to human cyclin A1 (CCNA1), each of said peptides comprising a polypeptide of general formula I: N-X-C, [I] wherein: (a) N-X-C is a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10 or 9 amino acids in which X comprises an amino acid sequence that is selected from the group consisting of:
CCNA1(120-131) VDTGTLKSDLHF [SEQ ID NO:1], CCNA1(218-226) AETLYLAVN [SEQ ID NO:2], CCNA1(227-235) FLDRFLSCM [SEQ ID NO:3],
10 CCNA1(253-261) ASKYEEIYP [SEQ ID NO:4], CCNA1(118-127) YEVDGTLKS [SEQ ID NO:5], CCNA1(167-175) YAEIYQYL [SEQ ID NO:6], CCNA1(330-339) LEADPFLKYL [SEQ ID NO:7], and CCNA1(341-351) SLIAAAAFCLA [SEQ IN NO:8], (b) N is an amino terminus of the peptide and consists of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino acids that are
15 independently selected from natural amino acids and non-natural amino acids, and (c) C is a carboxy terminus of the peptide and consists of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino acids that are independently selected from natural amino acids and non-natural amino acids.

In certain further embodiments of the above described methods
20 the step of administering comprises administering an immunogenic composition comprising one or more recombinant expression vectors that comprise the one or more isolated polynucleotides, each of said isolated polynucleotide being operably linked to an expression control sequence. In a further embodiment the vector is capable of delivering the polynucleotide to an antigen-presenting
25 cell. In a still further embodiment the antigen-presenting cell is a dendritic cell. In certain other further embodiments of the above described methods, the condition characterized by CCNA1 overexpression is a leukemia, which in certain further embodiments is acute myeloid leukemia.

Turning to another embodiment, there is provided a method for
30 treating a condition characterized by CCNA1 overexpression in cells of a subject, comprising: (A) contacting in vitro, under conditions and for a time

sufficient for antigen processing and presentation by antigen-presenting cells to take place, (i) a population of antigen-presenting cells that are immunocompatible with the subject, and (ii) an isolated peptide capable of eliciting an antigen-specific T-cell response to human cyclin A1 (CCNA1),
5 comprising a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8 or 7 amino acids wherein the polypeptide comprises a sequence of at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 contiguous amino acids from the CCNA1 amino acid sequence set forth in SEQ ID NO:9; and (B) administering one or a plurality of said antigen-pulsed antigen-presenting cells
10 to the subject in an amount effective to elicit said antigen-specific T-cell response to human cyclin A1 (CCNA1).

In another embodiment there is provided a method for treating a condition characterized by CCNA1 overexpression in cells of a subject, comprising: (A) contacting in vitro, under conditions and for a time sufficient for
15 antigen processing and presentation by antigen-presenting cells to take place, (i) a population of antigen-presenting cells that are immunocompatible with the subject, and (ii) an isolated peptide capable of eliciting an antigen-specific T-cell response to human cyclin A1 (CCNA1), comprising a polypeptide of general formula I: N-X-C, [I] wherein: (a) N-X-C is a polypeptide of no more than 20, 19,
20 18, 17, 16, 15, 14, 13, 12, 11, 10 or 9 amino acids in which X comprises an amino acid sequence that is selected from: CCNA1(120-131) VDTGTLKSDLHF [SEQ ID NO:1], CCNA1(218-226) AETLYLAVN [SEQ ID NO:2], CCNA1(227-235) FLDRFLSCM [SEQ ID NO:3], CCNA1(253-261) ASKYEEIYP [SEQ ID NO:4], CCNA1(118-127) YEVDGTLKS [SEQ ID NO:5],
25 CCNA1(167-175) YAEIYQYL [SEQ ID NO:6], CCNA1(330-339) LEADPFLKYL [SEQ ID NO:7], and CCNA1(341-351) SLIAAAAFCLA [SEQ IN NO:8], (b) N is an amino terminus of the peptide and consists of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino acids that are independently selected from natural amino acids and non-natural amino acids, and (c) C is a carboxy terminus of
30 the peptide and consists of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino acids that are independently selected from natural amino acids and non-natural amino

acids, and thereby obtaining a population of antigen-pulsed antigen-presenting cells; and (B) administering one or a plurality of said antigen-pulsed antigen-presenting cells to the subject in an amount effective to elicit said antigen-specific T-cell response to human cyclin A1 (CCNA1).

5 In another embodiment there is provided a method for treating a condition characterized by CCNA1 overexpression in cells of a subject, comprising: (A) contacting in vitro, under conditions and for a time sufficient for antigen processing and presentation by antigen-presenting cells to take place, (i) a population of antigen-presenting cells that are immunocompatible with the
10 subject, and (ii) a composition that comprises an isolated polynucleotide that can be expressed by said antigen-presenting cells and that encodes a peptide that is capable of eliciting an antigen-specific T-cell response to human cyclin A1 (CCNA1), the peptide comprising a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8 or 7 amino acids wherein the polypeptide
15 comprises a sequence of at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 contiguous amino acids from the CCNA1 amino acid sequence set forth in SEQ ID NO:9; and (B) administering one or a plurality of said antigen-pulsed antigen-presenting cells to the subject in an amount effective to elicit said antigen-specific T-cell response to human cyclin A1 (CCNA1).

20 In another embodiment there is provided a method for treating a condition characterized by CCNA1 overexpression in cells of a subject, comprising: (A) contacting in vitro, under conditions and for a time sufficient for antigen processing and presentation by antigen-presenting cells to take place, (i) a population of antigen-presenting cells that are immunocompatible with the
25 subject, and (ii) a composition that comprises an isolated polynucleotide that can be expressed by said antigen-presenting cells and that encodes a peptide that is capable of eliciting an antigen-specific T-cell response to human cyclin A1 (CCNA1), the peptide comprising a polypeptide of general formula I: N-X-C, [I] wherein: (a) N-X-C is a polypeptide of no more than 20, 19, 18, 17, 16, 15,
30 14, 13, 12, 11, 10 or 9 amino acids in which X comprises an amino acid sequence that is selected from: CCNA1(120-131) VDTGTLKSDLHF [SEQ ID

NO:1], CCNA1(218-226) AETLYLAVN [SEQ ID NO:2], CCNA1(227-235)
FLDRFLSCM [SEQ ID NO:3], CCNA1(253-261) ASKYEEIYP [SEQ ID NO:4],
CCNA1(118-127) YEVDTGTLKS [SEQ ID NO:5], CCNA1(167-175)
YAEIYQYL [SEQ ID NO:6], CCNA1(330-339) LEADPFLKYL [SEQ ID NO:7],
5 and CCNA1(341-351) SLIAAAAFCLA [SEQ IN NO:8], (b) N is an amino
terminus of the peptide and consists of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino
acids that are independently selected from natural amino acids and non-natural
amino acids, and (c) C is a carboxy terminus of the peptide and consists of 0, 1,
2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino acids that are independently selected from
10 natural amino acids and non-natural amino acids, and thereby obtaining a
population of antigen-pulsed antigen-presenting cells; and (B) administering
one or a plurality of said antigen-pulsed antigen-presenting cells to the subject
in an amount effective to elicit said antigen-specific T-cell response to human
cyclin A1 (CCNA1).

15 In certain further embodiments of the just-described methods, the
method further comprises a step of expanding the number of antigen-
presenting cells by culturing the antigen-presenting cells after the step of
contacting and prior to the step of administering. In certain other further
embodiments of the just-described methods, the method further comprises (C)
20 (1) contacting the antigen-pulsed antigen-presenting cells with one or a plurality
of immunocompatible T-cells after step (A), under conditions and for a time
sufficient to generate CCNA1-specific T-cells, and (2) adoptively transferring
the CCNA1-specific T-cells to the subject. In certain still further embodiments,
step (B) is omitted.

25 In certain other further embodiments of the just-described
methods, the method further comprises (C) (1) contacting the antigen-pulsed
antigen-presenting cells with one or a plurality of immunocompatible T-cells
after step (A), under conditions and for a time sufficient to generate CCNA1-
specific T-cells, (2) expanding the CCNA1-specific T-cells to obtain one or more
30 clones of said CCNA1-specific T-cells in amounts sufficient for T-cell receptor
structural characterization, (3) determining a T-cell receptor polypeptide

encoding nucleic acid sequence for one or more of said CCNA1-specific T-cells, (4) transfecting an adoptive transfer T-cell population with at least one T-cell receptor polypeptide encoding nucleic acid having a sequence determined in (3) to obtain engineered CCNA1-specific adoptive transfer T-cells, and 4) 5 adoptively transferring the engineered CCNA1-specific adoptive transfer T-cells to the subject. In certain still further embodiments, step (B) is omitted.

These and other aspects and embodiments of the herein described invention will be evident upon reference to the following detailed 10 description and attached drawings. All of the U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification and/or listed in the Application Data Sheet are incorporated herein by reference in their entirety, as if each was incorporated individually. Aspects and embodiments of 15 the invention can be modified, if necessary, to employ concepts of the various patents, applications and publications to provide yet further embodiments.

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

Figure 1 shows model-based expression of probe set 205899_at representing CCNA1: (A) Expression in AML LSC compared to HSCs/CD34+ 20 BM mononuclear cells, PBMCs and non-hematopoietic tissues, * $p < 0.001$ (explorative), (B) expression in AML LSCs and corresponding blasts.

Figure 2 shows CCNA1 expression quantified by qRT PCR: (A) in AML, healthy subsets of hematopoietic cells and tissues, (B) in AML FAB subtypes and BM of MDS and CML patients, (C) in healthy tissues.

25 Figure 3 shows HLA A*0201-restricted epitopes CCNA1₂₂₇₋₂₃₅ (A-C) and CCNA1₃₄₁₋₃₅₁ (D-F): (A, D) Mapping of the minimal immunogenic AA sequence using IFN γ intracellular staining (ICS). +/- refers to positivity of IFN γ after coincubation of the respective T-cell line with peptide pulsed autologous lymphoblastic cell lines (LCLs), (B, E) the immunogenic peptides stabilized HLA 30 A*0201 on T2 cells. Negative controls were T2 cells pulsed with an irrelevant

15-mer (shaded), (C, F) activation of specific clones was dependent on peptide and expression of HLA A*0201. IFN γ ICS with autologous LCLs, 721.211 cells, and 721.221 stably transfected with HLA A*0201 as APCs.

Figure 4 shows T-cell clones against CCNA1₂₂₇₋₂₃₅ [SEQ ID NO:3] and CCNA1₃₄₁₋₃₅₁ [SEQ ID NO:8] displayed cytotoxic activity. (A) Expression of CCNA1 in several myeloid cell lines quantified by qRT PCR, (B) IFN γ ICS: high avidity clones 2196.D9 and D11 produced IFN γ in the presence of CCNA1+/HLA A*0201+ cell line THP-1 independent of exogenous peptide; low avidity clone 2196.E1 only recognized peptide-pulsed cell lines, (C) 6h ⁵¹Cr release assay. Clone 2196.D11 caused specific lysis in THP-1. Low avidity clone 2196.E1 is shown for comparison, (D) Caspase-3 assay. Clones against both epitopes induced apoptosis in THP-1. Negative control: targets alone (shaded) and clone 2264.A1 specific for epitope CCNA1₁₁₈₋₁₂₇ [SEQ ID NO:5], which was HLA B*4001 restricted (data not shown, THP-1 was B*4001-negative), positive control: targets in presence of 4 μ M camptothecine. 2196.D9, 2196.D11 were specific for epitope CCNA1₂₂₇₋₂₃₅ [SEQ ID NO:3], clone 2264.E30 was specific for epitope CCNA1₃₄₁₋₃₅₁ [SEQ ID NO:8].

Figure 5 shows human cyclin A1 (CCNA1) isoform c amino acid (Fig. 5A)(SEQ ID NO:9) and encoding polynucleotide(Fig. 5B) (SEQ ID NO:10) sequences.

Figure 6 shows activity of T-cell clone 2196.D11_b specific for CCNA1₂₂₇₋₂₃₅ [SEQ ID NO:3] in an apoptosis induction (caspase-3) assay (Fig. 6A) and in a ⁵¹Cr release cytolysis assay (Fig. 6B).

DETAILED DESCRIPTION

Embodiments of the present invention as disclosed herein relate to the unexpected discoveries that the intracellular protein human cyclin A1 (CCNA1, *e.g.*, NCBI reference sequence (isoform c) NP_001104517.1, GI:161377472; NM_001111047.1 GI:161377471) is a leukemia-associated antigen (LAA), and that certain specific short peptides of at least 9, 10, 11 or 12 contiguous amino acids from the CCNA1 sequence contain immunogenic

epitopes that are recognized by T-cells in a major histocompatibility complex (MHC) antigen-restricted (*e.g.*, HLA-restricted) manner. Surprisingly, despite the occurrence of CCNA1 as an intracellular protein with a limited cell type expression pattern and tissue distribution, as disclosed herein CCNA1 is a
5 cancer associated antigen and CCNA1-derived peptides are capable of eliciting CCNA1-specific T-cell responses. In certain preferred embodiments the herein described CCNA1-derived peptides are capable of eliciting CCNA1-specific cytotoxic lymphocyte (CTL) responses by class I HLA-restricted CD8⁺ T-cells.

As described in greater detail below, the intracellular protein
10 CCNA1, which has been previously shown in murine studies to contribute to leukemogenesis and to promote cell proliferation and survival, has been detected in the LSC compartment of approximately 50% of all AML patients, and is not detectable in other tissues with the exception of the testis. Using dendritic cells pulsed with a peptide library spanning the entire CCNA1 isoform
15 c that is found in LSC, T-cells were generated that were capable of responding to many different CCNA1-derived oligopeptides. Eight CCNA1-derived peptides were identified that were immunogenic for T-cells, two of which were more fully characterized as immunogenic, HLA A*0201-restricted epitopes of CCNA1. T-cell clones specific for these epitopes recognized peptide-pulsed
20 target cells and also exhibited cytotoxicity against an HLA A*0201-positive AML line, THP-1, which endogenously expresses CCNA1.

The compositions and methods described herein will in certain embodiments have therapeutic utility for the treatment of diseases and conditions associated with CCNA1 overexpression (*e.g.*, detectable CCNA1
25 expression at a level that is greater in magnitude, in a statistically significant manner, than the level of CCNA1 expression that is detectable in a normal or disease-free cell). Such diseases include various forms of cancer and include without limitation hematologic malignancies that arise from CCNA1 overexpressing leukemia stem cells (LSC), for instance, acute myeloid
30 leukemia (AML). Non-limiting examples of these and related uses are described herein and include *in vitro* and *in vivo* stimulation of CCNA1 antigen-

specific T-cell responses, such as by the use of immunogenic CCNA1 peptides in peptide-based vaccines, the use of vaccines that are based on engineered polynucleotides that encode such immunogenic CCNA1 peptides or additional immunogenic peptides present in CCNA1, or the use of larger fragments or the
5 whole CCNA1 protein to induce T-cell responses.

Also contemplated, by way of illustration and not limitation, are immunotherapeutic protocols involving the adoptive transfer to a subject (*e.g.*, an AML patient) of antigen-presenting cells that have been pulsed *in vitro* with immunogenic CCNA1 peptides or with CCNA1 protein or that have been
10 modified to express immunogenic CCNA1 peptides, and/or adoptive transfer to the subject of CCNA-1-specific T-cells that have been induced *in vitro* by exposure to antigen-presenting cells that have been pulsed *in vitro* with immunogenic CCNA1 peptides. Principles of antigen processing by antigen presenting cells (APC) such as dendritic cells, macrophages, lymphocytes and
15 other cell types, and of antigen presentation by APC to T-cells, including major histocompatibility complex- (MHC) restricted presentation between immunocompatible (*e.g.*, sharing at least one allelic form of an MHC gene that is relevant for antigen presentation) APC and T-cells, are well established (see, *e.g.*, Murphy, Janeway's Immunobiology (8th Ed.) 2011 Garland Science, NY;
20 chapters 6, 9 and 16). Adoptive transfer protocols using unselected or selected T-cells are known in the art (*e.g.*, US2011/0052530, US2010/0310534; Ho et al., 2006 *J. Imm. Meth.* 310:40; Ho et al., 2003 *Canc. Cell* 3:431) and may be modified according to the teachings herein for use with transfer cell populations containing T-cells that are specifically induced by one or more immunogenic
25 CCNA1-derived T-cell epitope-containing peptides.

As another non-limiting example, certain presently disclosed embodiments contemplate cloning CCNA1-reactive T-cells that have been induced *in vitro* by exposure to antigen-presenting cells that have been pulsed
in vitro with immunogenic CCNA1 peptides, and from such T-cells identifying
30 and cloning the functional (*e.g.*, productively rearranged) T-cell receptor (TCR) encoding genes, which may then be used to transfect/transduce a T-cell

population for adoptive transfer into subjects. Recent advances in TCR sequencing have been described (e.g., Robins et al., 2009 *Blood* 114:4099; Robins et al., 2010 *Sci. Translat. Med.* 2:47ra64, PMID: 20811043; Robins et al. 2011 (Sept. 10) *J. Imm. Meth.* Epub ahead of print, PMID: 21945395; 5 Warren et al., 2011 *Genome Res.* 21:790) and may be employed in the course of practicing these embodiments according to the present disclosure. Similarly, methods for transfecting/transducing T-cells with desired nucleic acids have been described (e.g., US2004/0087025) as have adoptive transfer procedures using T-cells of desired antigen-specificity (e.g., Schmitt et al., 2009 *Hum. Gen.* 10 20:1240; Dossett et al., 2009 *Mol. Ther.* 17:742; Till et al., 2008 *Blood* 112:2261; Wang et al., 2007 *Hum. Gene Ther.* 18:712; Kuball et al., 2007 *Blood* 109:2331; US2011/0243972; US2011/0189141; Leen et al., 2007 *Ann. Rev. Immunol.* 25:243), such that adaptation of these methodologies to the presently disclosed embodiments is contemplated, based on the teachings herein, 15 including those that are directed to specific CCNA1-derived peptides that are capable of eliciting antigen-specific T-cell responses.

Presently disclosed T-cell immunogens, for use in inducing or eliciting immune responses against inappropriately CCNA1-overexpressing cells such as cancer cells, include isolated peptides that are capable of eliciting 20 an antigen-specific T-cell response to human cyclin A1 (CCNA1), each peptide comprising at least one of a full length CCNA1 polypeptide or a CCNA1-derived polypeptide of no more than 400, 350, 300, 250, 200, 150, 125, 100, 80, 70, 60, 50, 40, 30, 25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8 or 7 amino acids wherein the polypeptide comprises a sequence of at least 7, 8, 9, 10, 11, 12, 25 13, 14, 15, 16, 17, 18, 19 or 20, or 400, 350, 300, 250, 200, 150, 125, 100, 80, 70, 60, 50, 40, 30, 25 contiguous amino acids from the CCNA1 amino acid sequence set forth in SEQ ID NO:9. CCNA1-overexpressing cells cancer cells include cells of hematologic malignancies such as lymphoma and leukemia, and in particular, leukemia stem cells and/or acute myeloid leukemia cells.

According to certain presently disclosed embodiments, an isolated peptide capable of eliciting an antigen-specific T-cell response to human cyclin A1 (CCNA1), comprises a polypeptide of general formula I:



5 wherein:

(a) N-X-C is a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10 or 9 amino acids in which X comprises an amino acid sequence that is selected from:

- 10 CCNA1(120-131) VDTGTLKSDLHF [SEQ ID NO:1],
- CCNA1(218-226) AETLYLAVN [SEQ ID NO:2],
- CCNA1(227-235) FLDRFLSCM [SEQ ID NO:3],
- CCNA1(253-261) ASKYEEIYP [SEQ ID NO:4],
- CCNA1(118-127) YEVDTGTLKS [SEQ ID NO:5],
- CCNA1(167-175) YAEIYQYL [SEQ ID NO:6],
- 15 CCNA1(330-339) LEADPFLKYL [SEQ ID NO:7], and
- CCNA1(341-351) SLIAAAAFCLA [SEQ IN NO:8],

and also wherein:

(b) N is an amino terminus of the peptide and consists of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino acids that are independently selected from
 20 natural and non-natural amino acids amino acids, and wherein (c) C is a carboxy terminus of the peptide and consists of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino acids that are independently selected from natural and non-natural amino acids amino acids.

Accordingly in these and other embodiments it will be appreciated
 25 that the amino terminus of certain CCNA1-derived peptides disclosed herein as comprising T-cell immunogenic epitopes may consist of 1-11 independently selected natural or non-natural amino acids, and/or that in certain embodiments the carboxy terminus of certain such peptides may consist of 1-11
 independently selected natural or non-natural amino acids, where such amino
 30 and carboxy termini may have any sequence so long as the isolated peptide is of no more than 9-20 amino acids and comprises N-X-C as recited herein, and

is capable of specifically eliciting an antigen-specific T-cell response to human cyclin A1 (CCNA1).

Disclosed herein are a number of representative CCNA1-derived peptides that comprise N-X-C according to formula [I] as recited herein, and
5 that are capable of specifically eliciting an antigen-specific T-cell response to human cyclin A1 (CCNA1). The presently contemplated invention embodiments, however, are not intended to be so limited such that in view of the present disclosure those familiar with the art will be able readily to make and use additional CCNA1 peptides (and variants thereof) that are
10 immunogenic for T-cells.

For example, determination of the three-dimensional structures of representative immunogenic CCNA1-derived peptides bearing T-cell epitopes as described herein may be made through routine methodologies such that substitution of one or more amino acids with selected natural or non-natural
15 amino acids can be virtually modeled for purposes of determining whether a so derived structural variant retains the space-filling, charge, hydrophilic and/or hydrophobic properties of presently disclosed species, including modeling of potential peptide affinity interactions with MHC peptide-binding grooves (*e.g.*, BIMAS molecular modeling software, described by Parker et al., *J. Immunol.*
20 152:163, 1994; Tsites database, Feller et al. 1991 *Nature* 349:720; Rothbard et al., 1988 *EMBO J.* 7:93-100; Deavin et al., 1996 *Mol. Immunol.* 33:145-155; and other HLA peptide binding prediction analyses). *See also*, for instance, Donate et al., 1994 *Prot. Sci.* 3:2378; Bradley et al., *Science* 309: 1868-1871 (2005); Schueler-Furman et al., *Science* 310:638 (2005); Dietz et al., *Proc. Nat. Acad. Sci. USA* 103:1244 (2006); Dodson et al., *Nature* 450:176 (2007); Qian et al., *Nature* 450:259 (2007); Raman *et al. Science* 327:1014-1018 (2010).
25 These and other references describe computer algorithms that may be used for related embodiments, such as for rational design of variants of the CCNA1-derived peptides bearing T-cell epitopes as provided herein (*e.g.*, SEQ ID
30 NOS:1-8), for instance, by allowing for determination of atomic dimensions from space-filling models (van der Waals radii) of energy-minimized conformations.

In view of the present disclosure that the CCNA1 polypeptide and CCNA1-derived peptides contain immunogenic epitopes, *e.g.*, the molecular structures that are specifically recognized by T-cells via the T cell receptor (TCR) including via MHC-restricted T-cell recognition, it is thus expressly contemplated that alterations (*e.g.*, increases or decreases that are detectable with statistical significance) in the immunogenicity of any given epitope-bearing CCNA1 peptide may be introduced by structural modification, for example, to obtain immunogenic CCNA1 peptide-derived variants. Means for enhancing the immunogenicity of a peptide-defined epitope are known in the art, and may include the altered peptide ligand (APL) approach by which structural modifications are made to a given peptide. Peptide variants of enhanced immunogenicity have been generated as APLs, as described in other antigen systems, for instance, by Abdul-Alim et al. (2010 *J. Immunol.* 184:6514); Douat-Casassus et al. (2007 *J. Med. Chem.* 50:1598); Carrabba et al. (2003 *Canc. Res.* 63:1560); and Shang et al. (2009 *Eur. J. Immunol.* 39:2248). Accordingly it will be appreciated from the present disclosure that CCNA1 peptide sequences include a large number of immunogenic epitopes for T-cells, such that CCNA1 fragments (*e.g.*, sequences of at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or 400, 350, 300, 250, 200, 150, 125, 100, 80, 70, 60, 50, 40, 30, 25 contiguous amino acids from the CCNA1 amino acid sequence set forth in SEQ ID NO:9) and/or variants as provided herein (including APLs) may be encompassed within certain embodiments.

Some additional non-limiting examples of computer algorithms that may be used for these and related embodiments, such as for rational design of variants of the herein described CCNA1 immunogenic peptide epitopes (*e.g.*, SEQ ID NOS:1-8), include NAMD, a parallel molecular dynamics code designed for high-performance simulation of large biomolecular systems, and VMD which is a molecular visualization program for displaying, animating, and analyzing large biomolecular systems using 3-D graphics and built-in scripting (see Phillips, *et al.*, *Journal of Computational Chemistry*, 26:1781-1802, 2005; Humphrey, *et al.*, "VMD - Visual Molecular Dynamics", *J. Molec.*

Graphics, 1996, vol. 14, pp. 33-38; see also the website for the Theoretical and Computational Biophysics Group, University of Illinois at Urbana-Champaign, at ks.uiuc.edu/Research/vmd/). Many other computer programs are known in the art and available to the skilled person and allow for determining atomic

5 dimensions from space-filling models (van der Waals radii) of energy-minimized conformations; for example, GRID, which seeks to determine regions of high affinity for different chemical groups, thereby enhancing binding; Monte Carlo searches, which calculate mathematical alignment; and CHARMM (Brooks et al. (1983) *J. Comput. Chem.* 4:187-217) and AMBER (Weiner et al (1981) *J.*

10 *Comput. Chem.* 106: 765), which assess force field calculations, and analysis (see also, Eisenfield et al. (1991) *Am. J. Physiol.* 261:C376-386; Lybrand (1991) *J. Pharm. Belg.* 46:49-54; Froimowitz (1990) *Biotechniques* 8:640-644; Burbam et al. (1990) *Proteins* 7:99-111; Pedersen (1985) *Environ. Health Perspect.* 61:185-190; and Kini et al. (1991) *J. Biomol. Struct. Dyn.* 9:475-488).

15 A variety of appropriate computational computer programs are also commercially available, such as from Schrödinger (Munich, Germany).

"Natural or non-natural amino acid" includes any of the common naturally occurring amino acids which serve as building blocks for the biosynthesis of peptides, polypeptides and proteins (e.g., alanine, cysteine,

20 aspartic acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, methionine, asparagine, proline, glutamine, arginine, serine, threonine, valine, tryptophan, tyrosine) and also includes modified, derivatized, enantiomeric, rare and/or unusual amino acids, whether naturally occurring or synthetic, for instance, hydroxyproline, hydroxylysine, desmosine,

25 isodesmosine, ϵ -N-methyllysine, ϵ -N-trimethyllysine, methylhistidine, dehydrobutyrine, dehydroalanine, α -aminobutyric acid, β -alanine, γ -aminobutyric acid, homocysteine, homoserine, citrulline, ornithine and other amino acids that may be isolated from a natural source and/or that may be chemically synthesized, for instance, as may be found in *Proteins, Peptides and*

30 *Amino Acids Sourcebook* (White, J.S. and White, D.C., 2002 Humana Press, Totowa, NJ) or in *Amino Acid and Peptide Synthesis* (Jones, J., 2002 Oxford

Univ. Press USA, New York) or in *Unnatural Amino Acids, ChemFiles Vol. 1, No. 5* (2001 Fluka Chemie GmbH; Sigma-Aldrich, St. Louis, MO) or in *Unnatural Amino Acids II, ChemFiles Vol. 2, No. 4* (2002 Fluka Chemie GmbH; Sigma-Aldrich, St. Louis, MO). Additional descriptions of natural and/or non-
5 natural amino acids may be found, for example, in Kotha, 2003 *Acc. Chem. Res.* 36:342; Maruoka et al., 2004 *Proc. Nat. Acad. Sci. USA* 101:5824; Lundquist et al., 2001 *Org. Lett.* 3:781; Tang et al., 2002 *J. Org. Chem.* 67:7819; Rothman et al., 2003 *J. Org. Chem.* 68:6795; Krebs et al., 2004 *Chemistry* 10:544; Goodman et al., 2001 *Biopolymers* 60:229; Sabat et al.,
10 2000 *Org. Lett.* 2:1089; Fu et al., 2001 *J. Org. Chem.* 66:7118; and Hruby et al., 1994 *Meths. Mol. Biol.* 35:249. The standard three-letter abbreviations and 1-letter symbols are used herein to designate natural and non-natural amino acids.

Other non-natural amino acids or amino acid analogues are
15 known in the art and include, but are not limited to, non-natural L or D derivatives (such as D-amino acids present in peptides), fluorescent labeled amino acids, as well as specific examples including O-methyl-L-tyrosine, L-3-(2-naphthyl)alanine, 3-methyl-phenylalanine, 3-idio-tyrosine, O-propargyl-tyrosine, homoglutamine, an O-4-allyl-L-tyrosine, a 4-propyl-L-tyrosine, a 3-
20 nitro-L-tyrosine, a tri-O-acetyl-GlcNAc β -serine, an L-Dopa, a fluorinated phenylalanine, an isopropyl-L-phenylalanine, a p-azido-L-phenylalanine, a p-acyl-L-phenylalanine, a p-acetyl-L-phenylalanine, an m-acetyl-L-phenylalanine, selenomethionine, telluromethionine, selenocysteine, an alkyne phenylalanine, an O-allyl-L-tyrosine, an O-(2-propynyl)-L-tyrosine, a p-ethylthiocarbonyl-L-
25 phenylalanine, a p-(3-oxobutanoyl)-L-phenylalanine, a p-benzoyl-L-phenylalanine, an L-phosphoserine, a phosphoserine, a phosphotyrosine, homopropargylglycine, azidohomoalanine, a p-iodo-phenylalanine, a p-bromo-L-phenylalanine, dihydroxy-phenylalanine, dihydroxyl-L-phenylalanine, a p-nitro-L-phenylalanine, an m-methoxy-L-phenylalanine, a p-iodo-phenylalanine,
30 a p-bromophenylalanine, a p-amino-L-phenylalanine, and an isopropyl-L-phenylalanine, trifluoroleucine, norleucine ("Nle"), D-norleucine ("dNle" or "D-

Nle”), 5-fluoro-tryptophan, para-halo-phenylalanine, homo-phenylalanine (“homo-Phe”), seleno-methionine, ethionine, S-nitroso-homocysteine, thia-proline, 3-thienyl-alanine, homo-allyl-glycine, trifluoroisoleucine, trans and cis-2-amino-4-hexenoic acid, 2-butynyl-glycine, allyl-glycine, para-azido-
5 phenylalanine, para-cyano-phenylalanine, para-ethynyl-phenylalanine, hexafluoroleucine, 1,2,4-triazole-3-alanine, 2-fluoro-histidine, L-methyl histidine, 3-methyl-L-histidine, β -2-thienyl-L-alanine, β -(2-thiazolyl)-DL-alanine, homopropargylglycine (HPG) and azidohomoalanine (AHA) and the like.

In certain embodiments a natural or non-natural amino acid may
10 be present that comprises an aromatic side chain, as found, for example, in phenylalanine or tryptophan or analogues thereof including in other natural or non-natural amino acids based on the structures of which the skilled person will readily recognize when an aromatic ring system is present, typically in the form of an aromatic monocyclic or multicyclic hydrocarbon ring system consisting
15 only of hydrogen and carbon and containing from 6 to 19 carbon atoms, where the ring system may be partially or fully saturated, and which may be present as a group that includes, but need not be limited to, groups such as fluorenyl, phenyl and naphthyl.

In certain embodiments a natural or non-natural amino acid may
20 be present that comprises a hydrophobic side chain as found, for example, in alanine, valine, isoleucine, leucine, proline, phenylalanine, tryptophan or methionine or analogues thereof including in other natural or non-natural amino acids based on the structures of which the skilled person will readily recognize when a hydrophobic side chain (*e.g.*, typically one that is non-polar when in a
25 physiological milieu) is present. In certain embodiments a natural or non-natural amino acid may be present that comprises a basic side chain as found, for example, in lysine, arginine or histidine or analogues thereof including in other natural or non-natural amino acids based on the structures of which the skilled person will readily recognize when a basic (*e.g.*, typically polar and
30 having a positive charge when in a physiological milieu) is present.

Polypeptides disclosed herein may include L- and/or D- amino acids so long as the biological activity (*e.g.*, CCNA1-specific immunogenicity for T-cells) of the polypeptide is maintained. The isolated CCNA1-derived polypeptides may comprise in certain embodiments any of a variety of known natural and artificial post-translational or post-synthetic covalent chemical modifications by reactions that may include glycosylation (*e.g.*, N-linked oligosaccharide addition at asparagine residues, O-linked oligosaccharide addition at serine or threonine residues, glycation, or the like), fatty acylation, acetylation, PEGylation, and phosphorylation. Polypeptides herein disclosed may further include analogs, alleles and allelic variants which may contain amino acid deletions, or additions or substitutions of one or more amino acid residues with other naturally occurring amino acid residues or non-natural amino acid residues.

Peptide and non-peptide analogs may be referred to as peptide mimetics or peptidomimetics, and are known in the pharmaceutical industry (Fauchere, *J. Adv. Drug Res.* 15:29 (1986); Evans et al. *J. Med. Chem.* 30: 1229 (1987)). These compounds may contain one or more non-natural amino acid residue(s), one or more chemical modification moieties (for example, glycosylation, pegylation, fluorescence, radioactivity, or other moiety), and/or one or more non-natural peptide bond(s) (for example, a reduced peptide bond: --CH₂-NH₂--). Peptidomimetics may be developed by a variety of methods, including by computerized molecular modeling, random or site-directed mutagenesis, PCR-based strategies, chemical mutagenesis, and others.

The term "isolated" means that the material is removed from its original environment (*e.g.*, the natural environment if it is naturally occurring). For example, a naturally occurring nucleic acid or polypeptide present in a living animal is not isolated, but the same nucleic acid or polypeptide, separated from some or all of the co-existing materials in the natural system, is isolated. Such nucleic acid could be part of a vector and/or such nucleic acid or polypeptide could be part of a composition (*e.g.*, a cell lysate), and still be isolated in that such vector or composition is not part of the natural environment for the nucleic

acid or polypeptide. The term “gene” means the segment of DNA involved in producing a polypeptide chain; it includes regions preceding and following the coding region “leader and trailer” as well as intervening sequences (introns) between individual coding segments (exons).

5 Certain embodiments relate to nucleic acids that encode the polypeptides contemplated herein, for instance, CCNA1-derived polypeptides that contain epitopes recognized by, and immunogenic for, T-cells. As one of skill in the art will recognize, a nucleic acid may refer to a single and/or a double stranded DNA, cDNA or RNA in any form, and may include a positive and a
10 negative strand of the nucleic acid which complement each other, including anti-sense DNA, cDNA and RNA. Also included are siRNA, microRNA, RNA—DNA hybrids, ribozymes, and other various naturally occurring or synthetic forms of DNA or RNA.

 Certain embodiments include nucleic acids contained in a vector.
15 One of skill in the art can readily ascertain suitable vectors for use with certain herein disclosed embodiments. A typical vector may comprise a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked, or which is capable of replication in a host organism. Some examples of vectors include plasmids, viral vectors, cosmids, and others. Some vectors
20 may be capable of autonomous replication in a host cell into which they are introduced (*e.g.* bacterial vectors having a bacterial origin of replication and episomal mammalian vectors), whereas other vectors may be integrated into the genome of a host cell upon introduction into the host cell and thereby replicate along with the host genome. Additionally, some vectors are capable
25 of directing the expression of genes to which they are operatively linked (these vectors may be referred to as “expression vectors”). According to related embodiments, it is further understood that, if one or more agents (*e.g.*, polynucleotides encoding CCNA1-derived immunogenic peptide epitopes, or variants thereof, as described herein) is co-administered to a subject, that each
30 agent may reside in separate or the same vectors, and multiple vectors (each

containing a different agent the same agent) may be introduced to a cell or cell population or administered to a subject.

In certain embodiments, the nucleic acid encoding the herein described CCNA1-derived polypeptides that contain epitopes recognized by
5 and immunogenic for T-cells, may be operatively linked to certain elements of a vector. For example, polynucleotide sequences that are needed to effect the expression and processing of coding sequences to which they are ligated may be operatively linked. Expression control sequences may include appropriate transcription initiation, termination, promoter and enhancer sequences; efficient
10 RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (*i.e.* Kozak consensus sequences); sequences that enhance protein stability; and possibly sequences that enhance protein secretion. Expression control sequences may be operatively linked if they are
15 contiguous with the gene of interest and expression control sequences that act in trans or at a distance to control the gene of interest.

In particular embodiments, the recombinant expression vector is delivered to an appropriate cell, for example, an antigen-presenting cell *i.e.*, a cell that displays a peptide/MHC complex on its cell surface (*e.g.*, a dendritic
20 cell) that will induce the desired CCNA1-specific cell-mediated immune response, such as CD8 T-cell response including a cytotoxic T lymphocyte (CTL) response. The recombinant expression vectors may therefore also include, for example, lymphoid tissue-specific transcriptional regulatory elements (TRE) such as a B lymphocyte, T lymphocyte, or dendritic cell specific
25 TRE. Lymphoid tissue specific TRE are known in the art (*see, e.g.*, Thompson et al., *Mol. Cell. Biol.* 12, 1043-53 (1992); Todd et al., *J. Exp. Med.* 177, 1663-74 (1993); Penix et al., *J. Exp. Med.* 178:1483-96 (1993)).

In certain configurations, recombinant expression vectors may contain polynucleotide sequences that encode dendritic cell (DC) maturation /
30 stimulatory factors. Exemplary stimulatory molecules include GM-CSF, IL-2, IL-4, IL-6, IL-7, IL-15, IL-21, IL-23, TNF α , B7.1, B7.2, 4-1BB, CD40 ligand

(CD40L), drug-inducible CD40 (iCD40), and the like. These polynucleotides are typically under the control of one or more regulatory elements that direct the expression of the coding sequences in dendritic cells. Maturation of dendritic cells contributes to successful vaccination (see, e.g., Banchereau et al., *Nat. Rev. Immunol.* 5:296-306 (2005); Schuler et al., *Curr. Opin. Immunol.* 15:138-147 (2003); Figdor et al., *Nat. Med.* 10:475-480 (2004)). Maturation can transform DCs from cells actively involved in antigen capture into cells specialized for T-cell priming. For example, engagement of CD40 by CD40L on CD4-helper T-cells is an important signal for DC maturation, resulting in potent activation of CD8+ T-cells. Such stimulatory molecules are also referred to as maturation factors or maturation stimulatory factors.

In addition to vectors, certain embodiments relate to host cells that comprise the vectors that are presently disclosed. One of skill in the art readily understands that many suitable host cells are available in the art. A host cell may include any individual cell or cell culture which may receive a vector or the incorporation of nucleic acids and/or proteins, as well as any progeny cells. The term also encompasses progeny of the host cell, whether genetically or phenotypically the same or different. Suitable host cells may depend on the vector and may include mammalian cells, animal cells, human cells, simian cells, insect cells, yeast cells, and bacterial cells. These cells may be induced to incorporate the vector or other material by use of a viral vector, transformation via calcium phosphate precipitation, DEAE-dextran, electroporation, microinjection, or other methods. For example, See Sambrook et al. *Molecular Cloning: A Laboratory Manual* 2d ed. (Cold Spring Harbor Laboratory, 1989).

In certain embodiments, immunogenic variants are provided of the herein described CCNA1-derived polypeptides that contain epitopes recognized by, and immunogenic for, T-cells; these variants include polypeptide species that have one or more amino acid substitutions, insertions, or deletions in the amino acid sequence relative to the sequences of formula (I) or SEQ ID NOS:1-8 as presented herein. Conservative substitutions of amino acids are well

known and may occur naturally in the polypeptide or may be introduced when the polypeptide is recombinantly produced. Amino acid substitutions, deletions, and additions may be introduced into a polypeptide using well-known and routinely practiced mutagenesis methods (see, e.g., Sambrook et al. *Molecular Cloning: A Laboratory Manual*, 3d ed., Cold Spring Harbor Laboratory Press, NY 2001)). Oligonucleotide-directed site-specific (or segment specific) mutagenesis procedures may be employed to provide an altered polynucleotide that has particular codons altered according to the substitution, deletion, or insertion desired. Deletion or truncation variants of specific peptides that may be used as immunogens may also be constructed by using convenient restriction endonuclease sites adjacent to the desired deletion. Subsequent to restriction, overhangs may be filled in and the DNA re-ligated. Alternatively, random mutagenesis techniques, such as alanine scanning mutagenesis, error prone polymerase chain reaction mutagenesis, and oligonucleotide-directed mutagenesis may be used to prepare immunogen polypeptide variants (see, e.g., Sambrook et al., *supra*). Species (or variants) of a particular CCNA1-derived immunogen (or polypeptide fragment thereof) may include a polypeptide immunogen that has at least 85%, 90%, 95%, or 99% amino acid sequence identity to any of the exemplary amino acid sequences disclosed herein (e.g., SEQ ID NOS:1-8, or polypeptides of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10 or 9 amino acids in which at least one of SEQ ID NOS:1-8 may be present).

These CCNA1-derived peptide immunogen variants retain one or more biological activities or functions of the respective CCNA1-derived peptide that is immunogenic for T-cells as described herein (e.g., SEQ ID NOS:1-8). In particular, such immunogens that are variants of a herein described CCNA1-derived peptide retain, in a statistically, clinically, or biologically significant manner, the capability to induce a T-cell response (including a cytotoxic T lymphocyte response). Given the many molecular biology, protein expression, and protein isolation techniques and methods routinely practiced in the art for introducing mutations in a polypeptide, preparing polypeptide fragments,

isolating the fragments and variants, and analyzing such products, immunogenic CCNA1 polypeptide variants and fragments thereof having the desired biological activities can be made readily and without undue experimentation based on the disclosure herein.

5 A variety of criteria known to persons skilled in the art indicate whether an amino acid that is substituted at a particular position in a peptide or polypeptide is conservative (or similar). For example, a similar amino acid or a conservative amino acid substitution is one in which an amino acid residue is replaced with an amino acid residue having a similar side chain. Similar amino acids may be included in the following categories: amino acids with basic side chains (*e.g.*, lysine, arginine, histidine); amino acids with acidic side chains (*e.g.*, aspartic acid, glutamic acid); amino acids with uncharged polar side chains (*e.g.*, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, histidine); amino acids with nonpolar side chains (*e.g.*, alanine, valine, 10 leucine, isoleucine, proline, phenylalanine, methionine, tryptophan); amino acids with beta-branched side chains (*e.g.*, threonine, valine, isoleucine), and amino acids with aromatic side chains (*e.g.*, tyrosine, phenylalanine, tryptophan). Proline, which is considered more difficult to classify, shares properties with amino acids that have aliphatic side chains (*e.g.*, leucine, valine, 15 isoleucine, and alanine). In certain circumstances, substitution of glutamine for glutamic acid or asparagine for aspartic acid may be considered a similar substitution in that glutamine and asparagine are amide derivatives of glutamic acid and aspartic acid, respectively. As understood in the art “similarity” between two polypeptides is determined by comparing the amino acid 20 sequence and conserved amino acid substitutes thereto of the polypeptide to the sequence of a second polypeptide (*e.g.*, using GENWORKS, Align, the BLAST algorithm, or other algorithms described herein and practiced in the art).

 As described herein for immunogenic peptide fragments of CCNA1, assays for assessing whether a respective variant folds into a 30 conformation comparable to the non-variant polypeptide or fragment include, for example, the ability of the protein to react with mono- or polyclonal antibodies

that are specific for native or unfolded epitopes, the retention of ligand-binding functions, and the sensitivity or resistance of the mutant protein to digestion with proteases (*see* Sambrook et al., *supra*). Such variants can be identified, characterized, and/or made according to methods described herein or other
5 methods known in the art, which are routinely practiced by persons skilled in the art.

Isolated/recombinant immunogens included in the immunogenic compositions described herein may be produced and prepared according to various methods and techniques routinely practiced in the molecular biology
10 and/or polypeptide purification arts. Construction of an expression vector that is used for recombinantly producing an immunogen of interest can be accomplished using any of numerous suitable molecular biology engineering techniques known in the art, including, without limitation, the standard techniques of restriction endonuclease digestion, ligation, transformation,
15 plasmid purification, and DNA sequencing, for example as described in Sambrook et al. (1989 and 2001 editions; *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, NY) and Ausubel et al. (*Current Protocols in Molecular Biology* (2003)). To obtain efficient transcription and translation, the polynucleotide sequence in each recombinant expression
20 construct includes at least one appropriate expression control sequence (also called a regulatory sequence), such as a leader sequence and particularly a promoter operably (*i.e.*, operatively) linked to the nucleotide sequence encoding the immunogen.

Methods that may be used for isolating and purifying a
25 recombinantly produced immunogenic peptide, by way of example, may include obtaining supernatants from suitable host cell/vector systems that secrete the recombinant immunogen into culture media and then concentrating the media using a commercially available filter. Following concentration, the concentrate may be applied to a single suitable purification matrix or to a series of suitable
30 matrices, such as an affinity matrix or an ion exchange resin. One or more reverse phase HPLC steps may be employed to further purify a recombinant

polypeptide. These purification methods may also be employed when isolating an immunogen from its natural environment. Methods for large scale production of one or more of the isolated/recombinant immunogens described herein include batch cell culture, which is monitored and controlled to maintain
5 appropriate culture conditions. Purification of the immunogen may be performed according to methods described herein and known in the art and that comport with laws and guidelines of domestic and foreign regulatory agencies.

The presence of a malignant condition in a subject refers to the presence of dysplastic, cancerous and/or transformed cells in the subject,
10 including, for example neoplastic, tumor, non-contact inhibited or oncogenically transformed cells, or the like (*e.g.*, hematologic cancers including lymphomas and leukemias, such as acute myeloid leukemia, chronic myeloid leukemia, etc.) which are known to the art and for which criteria for diagnosis and classification are established (*e.g.*, Hanahan and Weinberg, 2011 *Cell* 144:646;
15 Hanahan and Weinberg 2000 *Cell* 100:57; Cavallo et al., 2011 *Canc. Immunol. Immunother.* 60:319; Kyrigideis et al., 2010 *J. Carcinog.* 9:3). In preferred embodiments contemplated by the present invention, for example, such cancer cells may be cells of acute myeloid leukemia, B-cell lymphoblastic leukemia, T-cell lymphoblastic leukemia, or myeloma, including cancer stem cells that are
20 capable of initiating and serially transplanting any of these types of cancer (see, *e.g.*, see Park et al. 2009 *Molec. Therap.* 17:219).

The CCNA1-derived polypeptides that contain epitopes recognized by and immunogenic for T-cells, as described herein (*e.g.*, SEQ ID NOS:1-8, and variants thereof), may be functionally characterized according to
25 any of a large number of art accepted methodologies for assaying T-cell activity, including determination of T-cell activation or induction and also including determination of T-cell responses that are antigen-specific. Examples include determination of T-cell proliferation, T-cell cytokine release, antigen-specific T-cell stimulation, MHC-restricted T-cell stimulation, CTL activity (*e.g.*,
30 by detecting ⁵¹Cr release from pre-loaded target cells and/or by caspase-3 assay (*e.g.*, Jerome et al. 2003 *Apoptosis* 8:563; He et al., 2005 *J. Imm. Meth.*

304:43), changes in T-cell phenotypic marker expression, and other measures of T-cell functions. Procedures for performing these and similar assays are may be found, for example, in Lefkovits (*Immunology Methods Manual: The Comprehensive Sourcebook of Techniques*, 1998). See also *Current Protocols in Immunology*; Weir, *Handbook of Experimental Immunology*, Blackwell Scientific, Boston, MA (1986); Mishell and Shigii (eds.) *Selected Methods in Cellular Immunology*, Freeman Publishing, San Francisco, CA (1979); Green and Reed, *Science* 281:1309 (1998) and references cited therein.

Levels of cytokines may be determined according to methods described herein and practiced in the art, including for example, ELISA, ELISPOT, intracellular cytokine staining, and flow cytometry and combinations thereof (e.g., intracellular cytokine staining and flow cytometry). Immune cell proliferation and clonal expansion resulting from an antigen-specific elicitation or stimulation of an immune response may be determined by isolating lymphocytes, such as circulating lymphocytes in samples of peripheral blood cells or cells from lymph nodes, stimulating the cells with antigen, and measuring cytokine production, cell proliferation and/or cell viability, such as by incorporation of tritiated thymidine or non-radioactive assays, such as MTT assays and the like. The effect of an immunogen described herein on the balance between a Th1 immune response and a Th2 immune response may be examined, for example, by determining levels of Th1 cytokines, such as IFN- γ , IL-12, IL-2, and TNF- β , and Type 2 cytokines, such as IL-4, IL-5, IL-9, IL-10, and IL-13.

The level of a CTL immune response thus may be determined by any one of numerous immunological methods described herein and routinely practiced in the art. The level of a CTL immune response may be determined prior to and following administration of any one of the herein described CCNA1-derived polypeptides that contain epitopes recognized by, and immunogenic for, T-cells (or administration of a composition comprising a polynucleotide encoding such a polypeptide). Cytotoxicity assays for determining CTL activity may be performed using any one of several techniques and methods routinely

practiced in the art (see, e.g., Henkart et al., "Cytotoxic T-Lymphocytes" in *Fundamental Immunology*, Paul (ed.) (2003 Lippincott Williams & Wilkins, Philadelphia, PA), pages 1127-50, and references cited therein).

A binding partner or an antibody is said to be "immunospecific,"
5 "specific for" or to "specifically bind" an immunogen of interest if the antibody reacts at a detectable level with the immunogen or immunogenic fragment thereof, preferably with an affinity constant, K_A , of greater than or equal to about 10^4 M^{-1} , or greater than or equal to about 10^5 M^{-1} , greater than or equal to about 10^6 M^{-1} , greater than or equal to about 10^7 M^{-1} , or greater than or
10 equal to 10^8 M^{-1} . Affinity of an antibody for its cognate antigen is also commonly expressed as a dissociation constant K_D , and an antibody specifically binds to the immunogen of interest if it binds with a K_D of less than or equal to 10^{-4} M , less than or equal to about 10^{-5} M , less than or equal to about 10^{-6} M , less than or equal to 10^{-7} M , or less than or equal to 10^{-8} M .

15 Affinities of binding partners or antibodies can be readily determined using conventional techniques, for example, those described by Scatchard et al. (*Ann. N.Y. Acad. Sci. USA* 51:660 (1949)) and by surface plasmon resonance (SPR; BIAcore™, Biosensor, Piscataway, NJ). For surface plasmon resonance, target molecules are immobilized on a solid phase and
20 exposed to a binding partner (or ligand) in a mobile phase running along a flow cell. If ligand binding to the immobilized target occurs, the local refractive index changes, leading to a change in SPR angle, which can be monitored in real time by detecting changes in the intensity of the reflected light. The rates of change of the SPR signal can be analyzed to yield apparent rate constants for
25 the association and dissociation phases of the binding reaction. The ratio of these values gives the apparent equilibrium constant (affinity) (see, e.g., Wolff et al., *Cancer Res.* 53:2560-2565 (1993)).

Antigen-specific T-cell responses are typically determined by comparisons of observed T-cell responses according to any of the herein
30 described T-cell functional parameters (e.g., proliferation, cytokine release, CTL activity, altered cell surface marker phenotype, etc.) that may be made between

T-cells that are exposed to a cognate antigen in an appropriate context (*e.g.*, the antigen used to prime or activate the T-cells, when presented by immunocompatible antigen-presenting cells) and T-cells from the same source population that are exposed instead to a structurally distinct or irrelevant control antigen. A response to the cognate antigen that is greater, with statistical significance, than the response to the control antigen signifies antigen-specificity.

A biological sample may be obtained from a subject for determining the presence and level of an immune response to an immunogenic CCNA1-derived polypeptide as described herein that contains an epitope recognized by, and immunogenic for, T-cells. A "biological sample" as used herein may be a blood sample (from which serum or plasma may be prepared), biopsy specimen, body fluids (*e.g.*, lung lavage, ascites, mucosal washings, synovial fluid), bone marrow, lymph nodes, tissue explant, organ culture, or any other tissue or cell preparation from the subject or a biological source. Biological samples may also be obtained from the subject prior to receiving any immunogenic composition, which biological sample is useful as a control for establishing baseline (*i.e.*, pre-immunization) data.

With respect to all immunoassays and methods described herein for determining an immune response, a person skilled in the art will also readily appreciate and understand experimental control conditions that are appropriately included when practicing these methods. Concentrations of reaction components, types of buffers, temperature, and time periods sufficient to permit interaction of the reaction components can be determined and/or adjusted according to methods described herein and with which persons skilled in the art are familiar.

As generally referred to in the art, and as used herein, sequence identity and sequence homology may be used interchangeably and generally refer to the percentage of nucleotides or amino acid residues in a candidate sequence that are identical with, respectively, the nucleotides or amino acid residues in a native polynucleotide or polypeptide sequence, after aligning the

sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Preferably, an isolated peptide capable of eliciting an antigen-specific T-cell response to human cyclin A1 (CCNA1) as described
5 herein, or an encoding polynucleotide therefore, according to the embodiments disclosed herein shares at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, 96%, 97%, 98%, or 99% of the amino acid residues (or of the nucleotides in a polynucleotide encoding such a CCNA1-derived polypeptide) with the immunogenic peptides disclosed herein
10 as SEQ ID NOS:1-8. Such sequence identity may be determined according to well known sequence analysis algorithms, including those available from the University of Wisconsin Genetics Computer Group (Madison, WI), such as FASTA, Gap, Bestfit, BLAST, or others.

It has also been determined according to certain embodiments of
15 the present invention that N-terminus extensions of the CCNA1 T-cell epitope-containing peptides described herein can alter the affinity of the peptide binding to a class I major histocompatibility complex (MHC) antigen in association with which the peptide may be displayed on the surface of an antigen-presenting cell (APC), and/or binding of the peptide to the T-cell receptor of a CCNA1-specific
20 T-cell, while C-terminus extensions may also enhance binding and/or activity of the CCNA1-derived peptides. Accordingly, certain embodiments contemplate the use of one or more of the peptides having amino acid sequences set forth in SEQ ID NOS:1-8, and/or variants of such peptides as described herein, and certain embodiments may additionally or alternatively include the use of
25 polypeptides of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10 or 9 amino acids that include in their sequences any of these peptides. Hence, certain contemplated embodiments relate to CCNA1-derived T-cell immunogenic peptides having amino-terminal and/or carboxy-terminal peptide extensions in addition to the amino acid sequences set forth in SEQ ID NOS:1-
30 8, or variants thereof which, as described herein, may be selected for their

ability to elicit an antigen-specific T-cell response to CCNA1, such as a CTL response.

As understood by a person skilled in the medical art, the terms, “treat” and “treatment,” refer to medical management of a disease, disorder, or condition of a subject (*i.e.*, patient, host, who may be a human or non-human animal) (*see, e.g.*, Stedman’s Medical Dictionary). In general, an appropriate dose and treatment regimen provide one or more of the herein described CCNA1-derived peptide immunogens (*e.g.*, SEQ ID NOS:1-8 and variants thereof), and optionally an adjuvant, in an amount sufficient to provide therapeutic and/or prophylactic benefit. Therapeutic and/or prophylactic benefit resulting from therapeutic treatment and/or prophylactic or preventative methods include, for example an improved clinical outcome, wherein the object is to prevent or retard or otherwise reduce (*e.g.*, decrease in a statistically significant manner relative to an untreated control) an undesired physiological change or disorder, or to prevent or or retard or retard or otherwise reduce the expansion or severity of such disease or disorder. Beneficial or desired clinical results from treating a subject include, but are not limited to, abatement, lessening, or alleviation of symptoms that result from or are associated the disease or disorder to be treated; decreased occurrence of symptoms; improved quality of life; longer disease-free status (*i.e.*, decreasing the likelihood or the propensity that a subject will present symptoms on the basis of which a diagnosis of a disease is made); diminishment of extent of disease; stabilized (*i.e.*, not worsening) state of disease; delay or slowing of disease progression; amelioration or palliation of the disease state; and remission (whether partial or total), whether detectable or undetectable; and/or overall survival.

“Treatment” can also mean prolonging survival when compared to expected survival if a subject were not receiving treatment. Subjects in need of the methods and compositions described herein include those who already have the disease or disorder as well as subjects prone to have or at risk of developing the disease or disorder. Subjects in need of prophylactic treatment

include subjects in whom the disease, condition, or disorder is to be prevented (*i.e.*, decreasing the likelihood of occurrence or recurrence of the disease or disorder). The clinical benefit provided by the compositions (and preparations comprising the compositions) and methods described herein can be evaluated
5 by design and execution of *in vitro* assays, preclinical studies, and clinical studies in subjects to whom administration of the compositions is intended to benefit. The design and execution of the appropriate preclinical studies and clinical studies can be readily performed by persons skilled in the relevant art(s).

10 The isolated CCNA1-derived peptide immunogens (including synthetically or recombinantly produced peptides), or recombinant expression vectors encoding such peptide(s) may be administered to a subject in a pharmaceutically or physiologically acceptable or suitable excipient or carrier. Pharmaceutically acceptable excipients are biologically compatible vehicles,
15 *e.g.*, physiological saline, which are described in greater detail herein, that are suitable for administration to a human or other non-human subject including a non-human mammalian subject.

 With respect to administration of a recombinant expression vector, a therapeutically effective amount provides an amount of the polynucleotide
20 which is capable of producing a clinically desirable result (*i.e.*, a sufficient amount of the CCNA1-derived peptide immunogen is expressed to induce or enhance the immune response by T-cells specific for CCNA1 (*e.g.*, cell-mediated response, including a cytotoxic T cell response) in a statistically significant manner) in a treated human or non-human animal. As is well known
25 in the medical arts, the dosage for any one patient depends upon many factors, including the patient's size, weight, body surface area, age, the particular compound to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently. Doses will vary, but a preferred dose for administration of an immunogenic composition comprising a
30 recombinant expression vector is sufficient to provide approximately 10^6 to 10^{12} copies of the vector polynucleotide molecule.

Pharmaceutical compositions, including the CCNA1-specific T-cell immunogenic compositions described herein, may be administered in a manner appropriate to the disease or condition to be treated (or prevented) as determined by persons skilled in the medical art. An appropriate dose and a
5 suitable duration and frequency of administration of the compositions will be determined by such factors as the health condition of the patient, size of the patient (*i.e.*, weight, mass, or body area), the type and severity of the patient's disease, the particular form of the active ingredient, and the method of administration. In general, an appropriate dose and treatment regimen provide
10 the composition(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit (such as described herein, including an improved clinical outcome, such as more frequent complete or partial remissions, or longer disease-free and/or overall survival, or a lessening of symptom severity). For prophylactic use, a dose should be sufficient to prevent, delay the onset of, or
15 diminish the severity of a disease associated with disease or disorder. Prophylactic benefit of the immunogenic compositions administered according to the methods described herein can be determined by performing pre-clinical (including *in vitro* and *in vivo* animal studies) and clinical studies and analyzing data obtained therefrom by appropriate statistical, biological, and clinical
20 methods and techniques, all of which can readily be practiced by a person skilled in the art.

In general, the amount of an immunogen, including fusion polypeptides as described herein, present in a dose, or produced *in situ* by an encoding polynucleotide present in a dose, ranges from about 0.01 μg to about
25 1000 μg per kg of host. The use of the minimum dosage that is sufficient to provide effective therapy is usually preferred. Patients may generally be monitored for therapeutic or prophylactic effectiveness using assays suitable for the condition being treated or prevented, which assays will be familiar to those having ordinary skill in the art and which are described herein. When
30 administered in a liquid form, suitable dose sizes will vary with the size of the patient, but will typically range from about 1 ml to about 500 ml (comprising

from about 0.01 μg to about 1000 μg per kg) for a 10-60 kg subject. Optimal doses may generally be determined using experimental models and/or clinical trials. The optimal dose may depend upon the body mass, body area, weight, or blood volume of the subject. As described herein, the appropriate dose may
5 also depend upon the patient's (e.g., human) condition, that is, stage of the disease, general health status, as well as age, gender, and weight, and other factors familiar to a person skilled in the medical art.

For pharmaceutical compositions comprising a nucleic acid molecule such as the recombinant expression vectors described herein, the
10 nucleic acid molecule may be present within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid, and bacterial, viral and mammalian expression systems such as, for example, vector particles and recombinant expression constructs as provided herein. Techniques for incorporating a polynucleotide (e.g., DNA) into such expression
15 systems are well known to those of ordinary skill in the art. In other certain embodiments, the recombinant expression vector, which is typically DNA, may also be "naked," as described, for example, in Ulmer et al., *Science* 259:1745-49 (1993) and reviewed by Cohen, *Science* 259:1691-92 (1993). The uptake of naked DNA may be increased by coating the DNA onto biodegradable beads,
20 which are efficiently transported into the cells.

Nucleic acid molecules may be delivered into a cell according to any one of several methods described in the art (see, e.g., Akhtar et al., *Trends Cell Bio.* 2:139 (1992); *Delivery Strategies for Antisense Oligonucleotide Therapeutics*, ed. Akhtar, 1995, Maurer et al., *Mol. Membr. Biol.* 16:129-40
25 (1999); Hofland and Huang, *Handb. Exp. Pharmacol.* 137:165-92 (1999); Lee et al., *ACS Symp. Ser.* 752:184-92 (2000); U.S. Patent No. 6,395,713; International Patent Application Publication No. WO 94/02595); Selbo et al., *Int. J. Cancer* 87:853-59 (2000); Selbo et al., *Tumour Biol.* 23:103-12 (2002); U.S. Patent Application Publication Nos. 2001/0007666, and 2003/077829). Such
30 delivery methods known to persons having skill in the art, include, but are not restricted to, encapsulation in liposomes, by iontophoresis, or by incorporation

into other vehicles, such as biodegradable polymers; hydrogels; cyclodextrins (see, e.g., Gonzalez et al., *Bioconjug. Chem.* 10:1068-74 (1999); Wang et al., International Application Publication Nos. WO 03/47518 and WO 03/46185); poly(lactic-co-glycolic)acid (PLGA) and PLCA microspheres (also useful for
5 delivery of peptides and polypeptides and other substances) (see, e.g., U.S. Patent No. 6,447,796; U.S. Patent Application Publication No. 2002/130430); biodegradable nanocapsules; and bioadhesive microspheres, or by proteinaceous vectors (International Application Publication No. WO 00/53722). In another embodiment, the nucleic acid molecules can also be formulated or
10 complexed with polyethyleneimine and derivatives thereof, such as polyethyleneimine-polyethyleneglycol-N-acetylgalactosamine (PEI-PEG-GAL) or polyethyleneimine-polyethyleneglycol-tri-N-acetylgalactosamine (PEI-PEG-triGAL) derivatives (see also, e.g., U.S. Patent Application Publication No. 2003/0077829).

15 Certain of the presently disclosed invention embodiments include preventative treatment of a subject or cells, tissues or organs of a subject, that is suspected of having or of being susceptible to a condition associated with CCNA1 overexpression. The preventative treatment may be the same as or different from the regimen (dosing and schedule, as well as choice of
20 immunogenic CCNA1-derived peptide and/or other therapeutic agents such as antigen-presenting cells or adoptively transferred T-cells) employed to treat a subject or cells, tissues or organs of a subject that has been confirmed to have a condition associated with CCNA1 overexpression. Prevention and/or treatment may also include the use of vaccines comprising compositions
25 disclosed herein, for example by way of illustration and not limitation, one or more CCNA1-derived peptides that are immunogenic for antigen-specific T-cells.

Particular contemplated embodiments relate to immunotherapeutic regimens using the herein described compositions and
30 methods to elicit T-cell immune responses that are directed against leukemic stem cells (LSC). More particularly, and according to non-limiting theory, as

disclosed herein it is believed that by certain of the present embodiments, cytotoxic T lymphocyte (CTL) responses are elicited that are specifically targeted against LSC. These and related embodiments are thus believed to provide a highly specific approach to eliminate or substantially reduce LSC
5 populations in a subject, thereby providing benefits for the treatment of leukemias that are characterized by CCNA1 overexpression, such as acute myeloid leukemia (AML). These approaches also offer unprecedented advantages pertaining to the specificity afforded by the restricted pattern of CCNA1 overexpression, and to the avoidance of undesirable generalized toxic
10 effects that accompany many less target-specific immunotherapeutic approaches.

A condition associated with CCNA1 overexpression includes any disorder or condition in which underactivity, overactivity or improper activity of a CCNA1 cellular or molecular event is present, and typically results from
15 unusually high (with statistical significance) levels of CCNA1 expression on afflicted cells (*e.g.*, leukemic cells such as AML cells or leukemic stem cells), relative to normal cells. A subject having such a disorder or condition would benefit from treatment with a composition or method of the presently described embodiments. Some conditions associated with CCNA1 overexpression thus
20 may include acute as well as chronic disorders and diseases, such as those pathological conditions that predispose the subject to a particular disorder.

Some non-limiting examples of conditions associated with CCNA1 overexpression include hyperproliferative disorders, which refer to states of activated and/or proliferating cells (which may also be transcriptionally
25 overactive) in a subject including tumors, neoplasms, cancer, malignancy, etc. In addition to activated and/or proliferating cells, the hyperproliferative disorder may also include an aberration or dysregulation of cell death processes, whether by necrosis or apoptosis. Such aberration of cell death processes may be associated with a variety of conditions, including cancer (including primary,
30 secondary malignancies as well as metastasis) and other conditions.

According to certain embodiments, virtually any type of cancer that is characterized by CCNA1 overexpression may be treated through the use of compositions and methods disclosed herein, including but not limited to hematological cancers (*e.g.*, leukemia including acute myeloid leukemia (AML), T or B cell lymphomas, myeloma, and others) are considered. Furthermore, “cancer” may refer to any accelerated proliferation of cells, including solid tumors, ascites tumors, blood or lymph or other malignancies; connective tissue malignancies; metastatic disease; minimal residual disease following transplantation of organs or stem cells; multi-drug resistant cancers, primary or secondary malignancies, angiogenesis related to malignancy, or other forms of cancer. Also contemplated within the presently disclosed embodiments are specific embodiments wherein only one of the above types of disease is included, or where specific conditions may be excluded regardless of whether or not they are characterized by CCNA1 overexpression.

Certain methods of treatment or prevention contemplated herein include administering a composition that comprises a desired nucleic acid molecule such that it stably integrates into the chromosome of certain desired cells. For example, such compositions may be integrated into immune system cells (*e.g.*, antigen-presenting cells and/or T-cells) in order to promote a desired, CCNA1-targeted T-cell response.

As used herein, administration of a composition or therapy refers to delivering the same to a subject, regardless of the route or mode of delivery. Administration may be effected continuously or intermittently, systemically or locally. Administration may be for treating a subject already confirmed of having a recognized condition, disease or disease state, or for subjects susceptible to or at risk of developing such a condition, disease or disease state. Co-administration may include simultaneous and/or sequential delivery of multiple agents in any order and on any dosing schedule.

An effective amount of a therapeutic or pharmaceutical composition refers to an amount sufficient, at dosages and for periods of time needed, to achieve the desired clinical results or beneficial treatment, as

described herein. An effective amount may be delivered in one or more administrations. If the administration is to a subject already known or confirmed to have a disease or disease-state, the term “therapeutic amount” may be used in reference to treatment, whereas “prophylactically effective amount” may be used to describe administering an effective amount to a subject that is susceptible or at risk of developing a disease or disease-state as a preventative course.

Pharmaceutical Compositions

In certain embodiments of the disclosed invention, a pharmaceutical composition comprising at least one herein disclosed composition (*e.g.*, an isolated peptide capable of eliciting an antigen-specific T-cell response to human cyclin A1, or a recombinant expression vector encoding the same), is administered to a subject. As used herein, a pharmaceutical composition generally refers to the combination of an active pharmaceutical drug or other therapeutic agent and an excipient or carrier, whether inert or active, wherein the pharmaceutical composition comprises at least one isolated peptide capable of eliciting an antigen-specific T-cell response to CCNA1 (or a recombinant expression vector encoding the same) that is suitable for therapeutic use, including prophylactic use, *in vivo*, *in vitro*, or *ex vivo*.

In certain embodiments, the present invention relates to formulations of one or more compositions disclosed herein in pharmaceutically-acceptable excipients or carriers for administration to a cell or a subject either alone, or in combination, with one or more other modalities of therapy. It is understood that, if desired, a composition as disclosed herein may be administered in combination with other agents as well, including therapeutic agents. Such compositions may be synthesized *de novo* or purified from host cells or other biological sources.

It will be apparent that any of the pharmaceutical compositions described herein can contain pharmaceutically acceptable excipients or other carriers, and may contain acceptable salts. Such salts can be prepared, for

example, from pharmaceutically acceptable non-toxic bases, including organic bases (*e.g.* salts of primary, secondary and tertiary amines and basic amino acids) and inorganic bases (*e.g.* sodium, potassium, lithium, ammonium, calcium and magnesium salts).

5 While any suitable carrier known to those of ordinary skill in the art may be employed in the pharmaceutical compositions as described herein (*e.g.*, pharmaceutical compositions that comprise the presently disclosed isolated peptide capable of eliciting a CCNA1-specific T-cell response, or a recombinant expression vector encoding the same) the type of carrier will
10 typically vary depending on the mode of administration. Compositions of the present invention may in certain embodiments be formulated for any appropriate manner of administration, including for example, topical, oral, nasal, mucosal, intravenous, intratumor, rectal, parenteral, intraperitoneal, subcutaneous and intramuscular administration.

15 Carriers for use with such pharmaceutical compositions are biocompatible, and may also be biodegradable. In certain embodiments, the formulation preferably provides a relatively constant level of active component release. In other embodiments, however, a more rapid rate of release immediately upon administration may be desired. The formulation of such
20 compositions is well within the level of ordinary skill in the art using known techniques. Illustrative carriers useful in this regard include microparticles of poly(lactide-co-glycolide), polyacrylate, latex, starch, cellulose, dextran and the like. Other illustrative delayed-release carriers include supramolecular biovectors, which comprise a non-liquid hydrophilic core (*e.g.*, a cross-linked
25 polysaccharide or oligosaccharide) and, optionally, an external layer comprising an amphiphilic compound, such as a phospholipid (*see e.g.*, U.S. Patent No. 5,151,254 and PCT applications WO 94/20078, WO/94/23701 and WO 96/06638). The amount of active compound contained within a sustained release formulation depends upon the route of administration, the rate and
30 expected duration of release and the nature of the condition to be treated or prevented.

Certain embodiments of the invention may utilize an alkalinizing agent, which is typically soluble in aqueous phase under physiological pH conditions. Such alkalinizing agents are well known to those in the art and may include alkali or alkaline-earth metal hydroxides, carbonates, bicarbonates,
5 phosphates, sodium borate, as well as basic salts (as discussed herein).

In another illustrative embodiment, biodegradable microspheres (e.g., polylactate polyglycolate) are employed as carriers for the compositions that are herein disclosed. Suitable biodegradable microspheres are disclosed, for example, in U.S. Patent Nos. 4,897,268; 5,075,109; 5,928,647; 5,811,128;
10 5,820,883; 5,853,763; 5,814,344, 5,407,609 and 5,942,252. Another illustrative carrier/delivery system employs a carrier comprising particulate-protein complexes, such as those described in U.S. Patent No. 5,928,647, which are capable of inducing a class I-restricted cytotoxic T lymphocyte response in a host.

15 In another illustrative embodiment, calcium phosphate core particles are employed as carriers, adjuvants, or as controlled release matrices for the compositions of this invention. In certain embodiments, an adjuvant may be necessary in order to increase the immune response of the subject. Adjuvants are well known in the art and may include cytokines, dead viruses or
20 bacteria or fragments thereof, antibodies, or any other agent that heightens an immune response.

The pharmaceutical compositions as provided herein will often further comprise one or more buffers (e.g., neutral buffered saline or phosphate buffered saline), carbohydrates (e.g., glucose, mannose, sucrose or dextrans),
25 mannitol, proteins, polypeptides or amino acids such as glycine, antioxidants, bacteriostats, chelating agents such as EDTA or glutathione, adjuvants (e.g., aluminum hydroxide), solutes that render the formulation isotonic, hypotonic or weakly hypertonic with the blood of a recipient, suspending agents, thickening agents and/or preservatives. Alternatively, compositions described herein may
30 be formulated as lyophilizates.

The pharmaceutical compositions described herein may be presented in unit-dose or multi-dose containers, such as sealed ampoules or vials. Such containers are typically sealed in such a way to preserve the sterility and stability of the formulation until use. In general, formulations may
5 be stored as suspensions, solutions or emulsions in oily or aqueous vehicles. Alternatively, a pharmaceutical composition may be stored in a freeze-dried condition requiring only the addition of a sterile liquid carrier immediately prior to use.

The development of suitable dosing and treatment regimens for
10 using the particular compositions described herein in a variety of treatment regimens, including *e.g.*, oral, parenteral, intravenous, intranasal, and intramuscular administration and formulation, is well known in the art, some of which are briefly discussed below for general purposes of illustration.

In certain applications, the pharmaceutical compositions disclosed
15 herein may be delivered via oral administration to an animal. As such, these compositions may be formulated with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard- or soft-shell gelatin capsule, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet. The pharmaceutical composition may take the form of
20 tablets, lozenges, pills, troches, capsules, elixirs, powders, granules, suspensions, emulsions, syrups, or tinctures. Slow-release or delayed-release forms may also be prepared (for example, in the form of coated particles, multi-layer tablets or microgranules).

The compositions may also contain any of a variety of additional
25 components, for example, pharmaceutically acceptable binders, such as gum tragacanth, gum acacia, sodium alginate, carboxymethylcellulose, polyethylene glycol, cornstarch, or gelatin; excipients, such as dicalcium phosphate; a disintegrating agent, such as corn starch, potato starch, methylcellulose, polyvinylpyrrolidone, xanthan gum, bentonite, agar, alginic acid and the like; a
30 lubricant, such as magnesium stearate; a sweetening agent, such as sucrose, lactose, glucose, aspartame or saccharin may be added; a diluent, such as

lactose, sorbitol, mannitol, dextrose, kaolin, cellulose, calcium carbonate, calcium silicate or dicalcium phosphate; a flavoring agent, such as peppermint, oil of wintergreen, orange, raspberry, bubblegum, or cherry flavoring, coating agents, such as polymers or copolymers of acrylic acid and/or methacrylic acid
5 and/or their esters, waxes, fatty alcohols, zein, shellac or gluten; preservatives, such as sodium benzoate, vitamin E, alpha-tocopherol, ascorbic acid, methyl paraben, propyl paraben, or sodium bisulphate; lubricants, such as magnesium stearate, stearic acid, sodium oleate, sodium chloride or talc; and/or time delay agents, such as glyceryl monostearate or glyceryl distearate.

10 In certain embodiments, a tablet or pill may be in the form of a compression coating or alternatively in the form of a spray coating. A compression coating may include a small tablet or pill utilized as part of the compression of a second tablet and wherein the small tablet is located nearly in the center of the rest of the powder compressed outside. A spray coating may
15 include an overcoating of a tablet with the coating preparation containing an active substance.

In certain embodiments, the pharmaceutical compositions of the present invention include "slow-release" or "immediate release" forms. As used herein, "slow-release" generally refers to a release of 20% to 60% in 1 hour and
20 greater than 70% in 6 hours or 40% to 80% in 2 hours, and greater than 70% in 6 hours in 500 ml of water (HCl 0.1N) in USP apparatus 1 (37° C, 100 RPM). Whereas, "immediate release" generally refers to a release of more than 70% in 30 minutes, in 500 ml of water (HCl 0.1N) in USP apparatus 1 (37°C, 100 RPM).

25 In certain embodiments, the tablet or pill weighs in the range of 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, and any value therebetween or greater. The oral dosage formulations of certain embodiments of the present invention may be manufactured according to known methods in the art, and may be packaged as known, including in a
30 moisture and/or oxygen and/or light protective packaging material.

In addition, liquid forms of the pharmaceutical compositions may include a liquid carrier, such as water, oils (olive oil, peanut oil, sesame oil, sunflower oil, safflower oil, arachis oil, coconut oil), liquid paraffin, ethylene glycol, propylene glycol, polyethylene glycol, ethanol, propanol, isopropanol, glycerol, fatty alcohols, triglycerides, or mixtures thereof.

If the subject composition is administered parenterally, the composition may also include sterile aqueous or oleaginous solution or suspension. Suitable non-toxic parenterally acceptable diluents or solvents include water, Ringer's solution, isotonic salt solution, 1,3-butanediol, ethanol, propylene glycol or polythethylene glycols in mixtures with water. Aqueous solutions or suspensions may further comprise one or more buffering agents, such as sodium acetate, sodium citrate, sodium borate or sodium tartrate. Of course, any material used in preparing any dosage unit formulation should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active compounds may be incorporated into sustained-release preparation and formulations. Dosage unit form, as used herein, refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit may contain a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms are largely dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic or prophylactic effect to be achieved, as well as the limitations inherent in the art of compounding such an active compound for treatment in subjects. Exemplary and non-limiting dosage ranges may be from 0.1-10 mg/kg, 1.0-20 mg/kg, 5.0-50 mg/kg, 10-100 mg/kg, or any values therebetween.

Typically, these formulations will contain at least about 0.01% of the active compound or more by weight of the active substance. However, the percentage of the active ingredient(s) may be varied and may conveniently be between about 1-99%, including about 60% or 70% or more of the weight or volume of the total formulation. Naturally, the amount of active compound(s) in

each therapeutically useful composition may be prepared in such a way that a suitable dosage will be obtained in any given unit dose of the compound.

Factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life, as well as other pharmacological

5 considerations will be contemplated by one skilled in the art of preparing such pharmaceutical formulations, and as such, a variety of dosages and treatment regimens may be desirable.

In certain circumstances it will be desirable to deliver the pharmaceutical compositions disclosed herein topically, orally, subcutaneously, 10 parenterally, intravenously, intramuscularly, or even intraperitoneally. Such approaches are well known to the skilled artisan, some of which are further described, for example, in U.S. Patent No. 5,543,158; U.S. Patent No. 5,641,515 and U.S. Patent No. 5,399,363. In certain embodiments, solutions of the active compounds as free base or pharmacologically acceptable salts may 15 be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations generally will contain a preservative to prevent the growth of microorganisms.

20 In one embodiment, for parenteral administration in an aqueous solution, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, a sterile 25 aqueous medium that can be employed will be known to those of skill in the art in light of the present disclosure. For example, one dosage may be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, "*Remington's Pharmaceutical Sciences*" 15th Edition, pages 1035-1038 and 1570-1580).

30 Some variation in dosage will necessarily occur depending on the condition of the subject being treated. Moreover, for human administration, preparations

preferably meet sterility, pyrogenicity, and the general safety and purity standards as required by FDA Office of Biologics standards.

In another embodiment of the invention, the compositions disclosed herein may be formulated in a neutral or salt form. Illustrative
5 pharmaceutically-acceptable salts include the acid addition salts (formed with the free amino groups of the protein) which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free
10 carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like. Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective.

15 The carriers can further comprise any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional
20 media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions. The phrase "pharmaceutically-acceptable" refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered
25 to a human.

In certain embodiments, the pharmaceutical compositions may be delivered by intranasal sprays, inhalation, and/or other aerosol delivery vehicles. Methods for delivering genes, nucleic acids, and peptide compositions directly to the lungs via nasal aerosol sprays have been
30 described, *e.g.*, in U.S. Patent No. 5,756,353 and U.S. Patent No. 5,804,212. Likewise, the delivery of drugs using intranasal microparticle resins (Takenaga

et al., *J Controlled Release* 1998 Mar 2; 52(1-2):81-7) and lysophosphatidyl-glycerol compounds (U.S. Patent No. 5,725,871) are also well-known in the pharmaceutical arts. An illustrative example of transmucosal drug delivery in the form of a polytetrafluoroethylene support matrix is described in U.S. Patent
5 No. 5,780,045.

In certain embodiments, liposomes, nanocapsules, microparticles, microencapsulation, lipid particles, vesicles, and the like, are used for the introduction of the presently disclosed compositions into suitable host cells/organisms. In particular, such compositions may be formulated for
10 delivery either encapsulated in a lipid particle, a liposome, a vesicle, a nanosphere, microsphere or microparticle, a nanoparticle or the like. Alternatively, compositions disclosed herein can be bound, either covalently or non-covalently, to the surface of such carrier vehicles.

The formation and use of liposome and liposome-like preparations
15 as potential drug carriers is generally known to those of skill in the art. Liposomes have been used successfully with a number of cell types that are normally difficult to transfect by other procedures, including T-cell suspensions, primary hepatocyte cultures and PC 12 cells (Renneisen *et al.*, *J Biol Chem.* 1990 Sep 25;265(27):16337-42; Muller *et al.*, *DNA Cell Biol.* 1990 Apr;9(3):221-
20 9). In addition, liposomes are free of the DNA length constraints that are typical of viral-based delivery systems. Liposomes have been used effectively to introduce genes, various drugs, radiotherapeutic agents, enzymes, viruses, transcription factors, allosteric effectors and the like, into a variety of cultured cell lines and animals. Furthermore, the use of liposomes does not appear to
25 be associated with autoimmune responses or unacceptable toxicity after systemic delivery.

In certain embodiments, liposomes are formed from phospholipids that are dispersed in an aqueous medium and spontaneously form multilamellar concentric bilayer vesicles (also termed multilamellar vesicles (MLVs)).
30

Alternatively, in other embodiments, the invention provides for pharmaceutically-acceptable nanocapsule formulations of the compositions of

the present invention. Nanocapsules can generally entrap compounds in a stable and reproducible way. To avoid side effects due to intracellular polymeric overloading, such ultrafine particles (sized around 0.1 μm) may be designed using polymers able to be degraded *in vivo*. Such particles can be made as described, for example, by Couvreur *et al.*, *Crit Rev Ther Drug Carrier Syst.* 1988;5(1):1-20; zur Muhlen *et al.*, *Eur J Pharm Biopharm.* 1998 Mar;45(2):149-55; Zambaux *et al.* *J Controlled Release* 1998 Jan 2;50(1-3):31-40; and U.S. Patent No. 5,145,684.

Dosing Schedules

10 Routes and frequency of administration of the therapeutic compositions described herein, as well as dosage, will vary from individual to individual, and may be readily established using standard techniques. In general, the pharmaceutical compositions may be administered by injection (e.g., intracutaneous, intramuscular, intravenous or subcutaneous), intranasally
15 (e.g., by aspiration) or orally. Suitable dosage formulations and methods of administering the agents are readily determined by those of skill in the art. In certain instances, the isolated peptide capable of eliciting a CCNA1-specific T-cell response to human cyclin A1 (or a recombinant expression vector encoding the same) may be administered at about 1 mg/kg, 5 mg/kg, 10mg/kg, 20mg/kg,
20 25mg/kg, 30mg/kg, 35mg/kg 40mg/kg, 45mg/kg, 50mg/kg, 60mg/kg, 70mg/kg, 75mg/kg, 80mg/kg, 90mg/kg, 100mg/kg, 125mg/kg, 150mg/kg, 175mg/kg, 200mg/kg or any value therebetween or greater. In certain instances, doses (and optionally, at least one other therapeutic agent dose) may be provided between 1 day and 14 days over a 30 day period. In certain instances, doses
25 (and optionally, at least one other therapeutic agent dose) may be provided 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days over a 60 day period. Alternate protocols may be appropriate for individual subjects. A suitable dose is an amount of a compound that, when administered as described above, is capable of altering or ameliorating symptoms, or is at least 10-50% above the basal

(i.e., untreated) level, which can be monitored by measuring specific levels of blood components, for example, detectable levels of circulating leukemic cells.

In general, an appropriate dosage and treatment regimen provides the active compound(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit. Such a response can be monitored by establishing an improved clinical outcome (e.g., more frequent remissions, complete or partial, or longer disease-free survival) in treated subjects as compared to non-treated subjects. Increases in preexisting immune responses to a tumor protein generally correlate with an improved clinical outcome. Such immune responses may generally be evaluated using standard proliferation, cytotoxicity or cytokine assays, which are routine in the art and may be performed using samples obtained from a subject before and after treatment.

Standard techniques may be used for recombinant DNA, peptide and oligonucleotide synthesis, immunoassays and tissue culture and transformation (e.g., electroporation, lipofection). Enzymatic reactions and purification techniques may be performed according to manufacturer's specifications or as commonly accomplished in the art or as described herein. These and related techniques and procedures may be generally performed according to conventional methods well known in the art and as described in various general and more specific references in microbiology, molecular biology, biochemistry, molecular genetics, cell biology, virology and immunology techniques that are cited and discussed throughout the present specification. See, e.g., Sambrook, et al., *Molecular Cloning: A Laboratory Manual*, 3d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; *Current Protocols in Molecular Biology* (John Wiley and Sons, updated July 2008); *Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology*, Greene Pub. Associates and Wiley-Interscience; Glover, *DNA Cloning: A Practical Approach*, vol. I & II (IRL Press, Oxford Univ. Press USA, 1985); *Current Protocols in Immunology* (Edited by: John E. Coligan, Ada M. Kruisbeek, David H. Margulies, Ethan M.

Shevach, Warren Strober 2001 John Wiley & Sons, NY, NY); *Real-Time PCR: Current Technology and Applications*, Edited by Julie Logan, Kirstin Edwards and Nick Saunders, 2009, Caister Academic Press, Norfolk, UK;

Anand, *Techniques for the Analysis of Complex Genomes*, (Academic Press, New York, 1992); Guthrie and Fink, *Guide to Yeast Genetics and Molecular Biology* (Academic Press, New York, 1991); *Oligonucleotide Synthesis* (N. Gait, Ed., 1984); *Nucleic Acid Hybridization* (B. Hames & S. Higgins, Eds., 1985); *Transcription and Translation* (B. Hames & S. Higgins, Eds., 1984); *Animal Cell Culture* (R. Freshney, Ed., 1986); Perbal, *A Practical Guide to Molecular Cloning* (1984); *Next-Generation Genome Sequencing* (Janitz, 2008 Wiley-VCH); *PCR Protocols (Methods in Molecular Biology)* (Park, Ed., 3rd Edition, 2010 Humana Press); *Immobilized Cells And Enzymes* (IRL Press, 1986); the treatise, *Methods In Enzymology* (Academic Press, Inc., N.Y.); *Gene Transfer Vectors For Mammalian Cells* (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); Harlow and Lane, *Antibodies*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1998); *Immunochemical Methods In Cell And Molecular Biology* (Mayer and Walker, eds., Academic Press, London, 1987); *Handbook Of Experimental Immunology*, Volumes I-IV (D. M. Weir and CC Blackwell, eds., 1986); Roitt, *Essential Immunology*, 6th Edition, (Blackwell Scientific Publications, Oxford, 1988); *Embryonic Stem Cells: Methods and Protocols* (Methods in Molecular Biology) (Kurstad Turksen, Ed., 2002); *Embryonic Stem Cell Protocols: Volume I: Isolation and Characterization* (Methods in Molecular Biology) (Kurstad Turksen, Ed., 2006); *Embryonic Stem Cell Protocols: Volume II: Differentiation Models* (Methods in Molecular Biology) (Kurstad Turksen, Ed., 2006); *Human Embryonic Stem Cell Protocols* (Methods in Molecular Biology) (Kursad Turksen Ed., 2006); *Mesenchymal Stem Cells: Methods and Protocols* (Methods in Molecular Biology) (Darwin J. Prockop, Donald G. Phinney, and Bruce A. Bunnell Eds., 2008); *Hematopoietic Stem Cell Protocols* (Methods in Molecular Medicine) (Christopher A. Klug, and Craig T. Jordan Eds., 2001); *Hematopoietic Stem Cell Protocols* (Methods in Molecular

Biology) (Kevin D. Bunting Ed., 2008) *Neural Stem Cells: Methods and Protocols* (Methods in Molecular Biology) (Leslie P. Weiner Ed., 2008).

Unless specific definitions are provided, the nomenclature utilized in connection with, and the laboratory procedures and techniques of, molecular
5 biology, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques may be used for recombinant technology, molecular biological, microbiological, chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment
10 of patients.

Each embodiment described in this specification is to be applied *mutatis mutandis* to every other embodiment unless expressly stated otherwise.

Unless the context requires otherwise, throughout the present specification and claims, the word “comprise” and variations thereof, such as,
15 “comprises” and “comprising” are to be construed in an open, inclusive sense, that is, as “including, but not limited to”. By “consisting of” is meant including, and typically limited to, whatever follows the phrase “consisting of.” By “consisting essentially of” is meant including any elements listed after the phrase, and limited to other elements that do not interfere with or contribute to
20 the activity or action specified in the disclosure for the listed elements. Thus, the phrase “consisting essentially of” indicates that the listed elements are required or mandatory, but that no other elements are required and may or may not be present depending upon whether or not they affect the activity or action of the listed elements.

25 In this specification and the appended claims, the singular forms “a,” “an” and “the” include plural references unless the content clearly dictates otherwise. As used herein, in particular embodiments, the terms “about” or “approximately” when preceding a numerical value indicates the value plus or minus a range of 5%, 6%, 7%, 8% or 9%. In other embodiments, the terms
30 “about” or “approximately” when preceding a numerical value indicates the value plus or minus a range of 10%, 11%, 12%, 13% or 14%. In yet other

embodiments, the terms “about” or “approximately” when preceding a numerical value indicates the value plus or minus a range of 15%, 16%, 17%, 18%, 19% or 20%.

Reference throughout this specification to “one embodiment” or “an embodiment” or “an aspect” means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, the appearances of the phrases “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments. When steps of a method are described or claimed, and the steps are described as occurring in a particular order, the description of a first step occurring (or being performed) “prior to” (*i.e.*, before) a second step has the same meaning if rewritten to state that the second step occurs (or is performed) “subsequent” to the first step.

The following Examples are presented by way of illustration and not limitation.

20

EXAMPLES

EXAMPLE 1

IDENTIFICATION OF HUMAN CYCLIN A1 (CCNA1) AS AN
IMMUNOTHERAPEUTIC TARGET FOR LEUKEMIA AND
CHARACTERIZATION OF CCNA1 T-CELL IMMUNOGENIC EPITOPES

25

In this Example, analyses of differential gene expression were performed to identify cyclin A1 (CCNA1), an intracellular protein, as a candidate new T-cell target protein. By way of brief background, CCNA1 was reported to regulate the progression of male germ cells through meiosis I and was

30

therefore selectively expressed in testis (Yang et al., 1997 *Cancer Res* 57 (5):913-920; Wolgemuth et al., 2004 *Int J Androl* 27 (4):192-199. doi:10.1111/j.1365-2605.2004.00480.x IJA480 [pii]). Published reports have shown that CCNA1 ^{-/-} mice were viable, and were phenotypically normal with the exception
5 of male infertility (Krug et al., 2009 *Int J Oncol* 34 (1):129-136; Nickerson et al., 2007 *Dev Biol* 306 (2):725-735. doi:S0012-1606 (07) 00783-X [pii] 10.1016/j.ydbio.2007.04.009). CCNA1 was also shown to be aberrantly expressed in AML as well as other malignancies (Yang et al., 1997 *Cancer Res* 57 (5):913-920; Stirewalt et al., 2008 *Genes Chromosomes Cancer* 47 (1):8-20.
10 doi:10.1002/gcc.20500). In AML, CCNA1 sustained the malignant phenotype through pro-proliferative and anti-apoptotic activities (Chan et al., 2009 *Oncogene* 28 (43):3825-3836. doi: onc 2009236 [pii] 10.1038/ onc.2009.236; Jang et al., 2008 *Cancer Res* 68 (12):4559-4570. doi: 68/12/ 4559 [pii] 10.1158/0008-5472.CAN-08-0021; Ji et al., 2007 *Int J Cancer* 121 (4):706-713.
15 doi:10.1002 /ijc. 22634), and over-expression of CCNA1 in mice caused dysplastic myelopoiesis and transplantable myeloid leukemias in 15% of the mice (Liao et al., 2001 *Proc Natl Acad Sci USA* 98 (12):6853-6858. doi:10.1073/ pnas.12154 0098 12154 0098 [pii]).

Here, CCNA1 is shown to act as a testis-leukemia-antigen
20 harboring a multitude of potentially immunogenic MHC class I epitopes that can be used to generate CD8⁺ T-cells from healthy donors. T-cells so generated were able to recognize and lyse leukemic cells.

Material and Methods

25 Human samples. For quantitative realtime PCR (qRT PCR), mononuclear cells of AML patients from peripheral blood and bone marrow (BM), BM mononuclear cells from chronic myeloid leukemia (CML) patients and patients with myelodysplastic syndrome (MDS), and GM-CSF-mobilized CD34+
30 cells were isolated by leukopheresis or Ficoll-Hypaque (Biochrom, Cambridge, UK). All AML samples contained more than 60% malignant cells (average 84%). Cells were collected at Fred Hutchinson Cancer Research Center

(FHCRC), Seattle, WA, USA, and at Charité Campus Benjamin Franklin, Berlin, Germany. For the generation of T-cell lines, leukopheresis products were obtained from two healthy donors at the FHCRC, Seattle. All samples were collected after written informed consent and with approval of the institutional
5 review boards of the respective institutions.

Cell lines. Epstein-Barr virus (EBV) transformed lymphoblastoid cell lines (LCLs) were generated as described (Riddell et al., 1991 *J Immunol* 146 (8):2795-2804). TM-LCL were used as feeder cells in the Rapid Expansion Protocol (REP) (Ho et al., 2006 *J Immunol Methods* 310 (1-2):40-52. doi:
10 S0022-1759 (05) 00429-1 [pii] 10.1016/ j.jim.2005. 11.023). The T-cell/B-cell hybrid cell line T2 used for presentation of epitopes expressed only HLA A*0201, but was TAP deficient. LCL 721.221 expressed no HLA class I due to a radiation induced deletion of the relevant alleles, and was stably transduced with the retroviral vector pLBPC containing HLA A*0201 (Akatsuka et al., 2002
15 *Tissue Antigens* 59 (6):502-511. doi: tan 590607 [pii]). LCLs and T2 cells were maintained as described (Ho et al., 2006 *J Immunol Methods* 310 (1-2):40-52. doi: S0022-1759 (05) 00429-1 [pii] 10.1016/ j.jim.2005. 11.023). Cell lines K562 (CML), THP-1, HL60, KG1 (AML) and U937 (monocytic cell line) were maintained in RPMI 1640 supplemented with 100 U/ml penicillin, 100 g/ml
20 streptomycin (Invitrogen, Carlsbad, CA), and 10% fetal bovine serum (FBS), and for THP-1, 50 M β -mercaptoethanol (Sigma, St. Louis, MO) was also added. CTLs and dendritic cells (DCs) were maintained as described (Ho et al., 2006 *J Immunol Methods* 310 (1-2):40-52).

Microarray data analysis. Two panels of microarray data sets
25 (Affymetrix, Santa Clara, CA) were used in this study: (1) nine AML LSC samples (Lineage⁻, CD34⁺, CD38⁻, CD90, (Majeti et al., 2009 *Proc Natl Acad Sci USA* 106 (9):3396-3401), seven corresponding leukemic blast samples (Lineage, CD34), four HSC samples (Lineage, CD34⁺, CD38⁻, CD90⁺ (Majeti et al., 2009 *Proc Natl Acad Sci USA* 106 (9):3396-3401)) and data sets of
30 peripheral blood mononuclear cells (PBMCs), CD34⁺ BM mononuclear cells and tissues (NCBI GEO server GSM279585-279588, 414970, 414972, 414975,

419165-419174, 457175-457177, 483480-483496, 80576, 80582, 80602, 80615, 80619, 80653, 80689, 80712, 80734, 80738, 80739, 80759, 80792, 80824, 80826, 80867, 80869, HG U133 plus 2.0 format); and (2) 30 samples of AML cells (>75% malignant cells, Stirewalt et al., 2008 *Genes Chromosomes Cancer* 47 (1):8-20; and unpublished) and 58 tissue samples (NCBI GEO server GSM18873, 18874, 18881, 18882, 18899-18906, 18909, 18910, 18917, 18918, 18921, 18922, 18943-18962, 18965, 18966, 18969-18974, 18977, 18978, 18981, 18982, 18995-18998, 19001, 19002, 19013, 19014, 44671-44693, 44699-44706, HG U133A format). Samples were normalized using the invariant set method (dChip 2.0 software, Li et al., 2001 *Proc Natl Acad Sci USA* 98 (1):31-36). Before analyzing the panels at a single-probe-set level, unsupervised hierarchical clustering was performed to rule out clustering in accordance to the origin of the samples rather than of the biological background of the data sets. Expression values of probe set 205899_at in LSCs were compared with other cell types using a two-tailed Mann-Whitney test. CCNA1 expression values of seven paired samples of LSC and the corresponding leukemic blasts (Lineage-, CD34-) were compared using a two-tailed Wilcoxon Signed Rank test.

Quantitative realtime PCR. Total RNA was extracted using Trizol reagent (Invitrogen) or RNeasy Mini Kit (Qiagen, Hilden, Germany). Reverse transcription was performed using Superscript III (Invitrogen) or Omniscript (Qiagen). A panel of cDNAs from pooled healthy tissues was purchased from Clontech (Mountain View, CA), and five samples of healthy BM were purchased from Cambrex (Rutherford, NJ). Quantitative two-step RT PCR was performed on an ABI 7500 machine (Applied Biosystems, Carlsbad, CA) with TA=60°C using the following primers and probes:

Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)_ fwd:
 GAG TCA ACG GAT TTG GTC GT; [SEQ ID NO:11]
 GAPDH_probe, labeled with 6FAM (6-carboxyfluorescein) at the
 5' end and TAMRA (carboxytetramethylrhodamine) at the 3' end:
 GAT ATT GTT GCC ATC AAT GAC CCC T [SEQ ID NO:12];

GAPDH_rev: GAC AAG CTT CCC GTT CTC AG [SEQ ID NO:13];
CCNA1_fwd: CAT GAA GAA GCA GCC AGA CA [SEQ ID

NO:14];

CCNA1_probe, labeled with 6FAM (6-carboxyfluorescein) at the 5'
5 end and TAMRA (carboxytetramethylrhodamine) at the 3' end:

TTC GAG CAG AGA CCC TGT ATC TGG [SEQ ID NO:15];

CCNA1_rev: TTC GAA GCC AAA AGC ATA GC [SEQ ID NO:16].

Crossing points were plotted against standard curves of
pCR4-TOPO plasmids (Invitrogen) containing the respective PCR product as
10 described (Keilholz et al., 2004 *Clin Cancer Res* 10 (5):1605-1612). All
reactions were performed in duplicate. CCNA1 expression is given as copies
per copies of GAPDH.

Cytokines and peptides. Recombinant human IL-1, IL-4, IL-7,
IL-15, and TNF α were obtained from R&D Systems (Minneapolis, MN), IL-2 and
15 GM-CSF from Chiron (Emeryville, CA), PGE2 from MP Biomedicals (Irvine,
CA), and IL-21 from Peprotech (Rocky Hill, NJ). A peptide library of a total of
103 15-mers with an overlap of 11 amino acids (AA) spanning CCNA1 (isoform
c, NM_001111046) was purchased from Sigma (St. Louis, MO). Shorter
peptides were purchased from Sigma or from JPT (Berlin, Germany).

20 Generation of CCNA1 specific T cell clones. T-cell lines were
generated as described with minor modifications (Ho et al., 2006 *J Immunol
Methods* 310 (1-2):40-52) . Briefly, DCs were derived from the plastic adherent
fraction of PBMCs by culture over two days (days -2 to 0) in DC media
(CellGenix, Freiburg, Germany) supplemented with GM-CSF (800 U/ml) and
25 IL-4 (1000 U/ml). On day -1, maturation cytokines TNF α (1100 U/ml), IL-1 β
(2000 U/ml), IL-6 (1000 U/ml) and PGE2 (1 μ g/ml) were added. On day 0, DCs
were harvested, washed and pulsed with peptide (single peptides at 10 μ g/ml or
peptide pools at 2 μ g/ml) over 2 to 4 h in serum-free DC media. CD8 T cells
were isolated from PBMCs using anti-CD8 microbeads (Miltenyi, Auburn, CA)
30 and stimulated with DCs at an effector target (E:T) ratio of 1:5 to 1:10 in the
presence of IL-21 (30 ng/ml). On day 3, IL-2 (12.5 U/ml), IL-7 (5 ng/ml) and

IL-15 (5 ng/ml) were added. Cells were restimulated between days 10 and 14 using the plastic adherent fraction of irradiated autologous PBMCs as antigen presenting cells (APCs) after being peptide-pulsed for two hours and in the presence of IL-21. After restimulation, cells were supplemented from day 1 on
5 with IL-2 (25 U/ml), IL-7 (5 ng/ml) and IL-15 (5 ng/ml). T-cell clones were generated by plating cells at limiting dilution and expanding with TM-LCLs coated with OKT3 (OrthoBiotech, Bridgewater, NJ) and allogeneic PBMCs as feeders (REP protocol) as described (Ho et al., 2006 *J Immunol Methods* 310 (1-2):40-52).

10 IFN γ intracellular staining (ICS). APCs were pulsed with 10 μ g/ml peptide overnight and washed once. Effector cells were coincubated with APCs for 6 h in RPMI containing 10% FBS in the presence of monensin. Cells were then stained with anti-CD8-FITC, permeabilized using the BD
15 Cytotfix/Cytoperm kit, and stained with anti-IFN γ -allophycocyanin (all from BD Bioscience, Franklin Lakes, NJ).

HLA stabilization assay. T2 cells were pulsed with 100 μ g/ml peptide in serum-free RPMI containing 1 μ g/ml β -2-microglobulin (Sigma) for 16 h. Cells were then washed and incubated for 4 h in the presence of 5 μ g/ml brefeldin A (Sigma), and then stained with FITC-labeled anti-HLA A, B, C (clone
20 W6/32, BD Bioscience).

Caspase-3 assay. Target cells were membrane-labeled with PKH26 (Sigma) according to the manufacturer's instructions. T-cell clones were used at the end of the Rapid Expansion Protocol (REP, Riddell and Greenberg, 1990 *J. Imm. Meth.* 128:189; Ho et al., 2006 *J. Imm. Meth.* 310:40)
25 cycle (day 12 or later). Targets and T-cells were incubated at an E:T ratio of 3:1 in 96-well round-bottom plates at 37°C for 4 h. As a negative control, targets were incubated without effectors, and, as a positive control, targets were incubated in the presence of 4 μ M camptothecin (Sigma) or 1 μ M staurosporine (Sigma). Cells were then fixed and permeabilized using the BD
30 Cytotfix/Cytoperm™ kit according to the supplier's instructions, and stained with

anti-active caspase-3 antibody conjugated either to FITC or Alexa-Fluor-647 (C92-625, BD Bioscience).

⁵¹Chromium release assay. A standard ⁵¹Cr release assay was performed as described (Ho et al., 2006 *J Immunol Methods* 310 (1-2):40-52) using 5000 target cells and T-cells at the end of the REP cycle (day 12 or later) at E:T ratios of 10-1.25:1 per well in triplicate. Spontaneous release was assessed by incubating targets in the absence of effectors. Percentage of specific lysis was calculated using the formula $100 \times (\text{experimental release} - \text{spontaneous release}) / (\text{maximum release} - \text{spontaneous release})$.

10

Results

Selective expression of CCNA1 in AML LSC, leukemic blasts and testis. To systematically screen for candidate target genes for T-cell mediated therapy that were selectively expressed in the AML LSC compartment with or without expression in other leukemic cell populations, nine LSC microarray data sets were analyzed along with samples of different hematopoietic cell subsets and non-hematopoietic tissues. Suitable candidate genes were identified by mathematical filtering and manual vetting of the model-based expression values. Based on the microarray data and published data on oncogenicity and cellular location of the respective genes, eight candidates including WT1 were identified, but only probe set 205899_at representing CCNA1 revealed selective expression in LSCs and AML blasts in the two independent microarray data sets and a third set of samples analyzed using qRT PCR.

In the first microarray set, CCNA1 was overexpressed in six out of nine analyzed LSC samples and testis. Expression values of CCNA1 were significantly higher in LSCs than in HSCs/CD34+ BM mononuclear cells, PBMCs, and a panel of tissue samples including testis (Figure 1A). Statistical testing was performed on the array set actually used to select the target. Since no significant difference in CCNA1 expression was observed between the LSCs and leukemic blasts derived from the same patients (Figure 1B), the expression pattern of CCNA1 was confirmed in additional sample sets not selected for

30

LSCs. Parts of the second microarray data panel, in which CCNA1 was previously identified as being expressed at significantly higher levels in AML cells compared to BM CD34+ mononuclear cells, PBMCs, mobilized CD34+ cells and BM, have already been published (Stirewalt et al., 2008 *Genes Chromosomes Cancer* 47 (1):8-20). These AML data sets were now analyzed along with data sets of non-hematopoietic tissues and lymphatic organs including two specimens of testis tissue. Again, expression of CCNA1 was only detected in AML and testis, and its expression was significantly higher in AML than in the tissue samples from testis ($p=0.0017$).

10 To confirm the *in silico* findings and the validity of probe set 205899_at, CCNA1 was quantified in AML samples, in other hematopoietic cell subsets, and in a panel of non-hematopoietic tissues using qRT-PCR. Of 33 AML samples analyzed, 17 samples revealed expression of CCNA1 at levels at least twice as high as in every physiological sample measured except testis.

15 No difference was observed between the CCNA1 expression levels in BM and G-CSF mobilized CD34+ mononuclear cells, which in both cases were very low. Lowest expression levels were found in maximally proliferating T-cells after OKT3 stimulation (Figure 2 A). Analyzing different French-American-British (FAB) AML subtypes and BM samples from patients with CML and MDS,

20 variable percentages of aberrant CCNA1 expression were observed in AML, with the highest expression levels in acute promyelocytic leukemia (APL) and no overexpression in patients with secondary AML, MDS or CML (Figure 2B). The median expression of CCNA1 copy numbers per GAPDH in the AML samples was approximately one order of magnitude higher than the expression

25 of WT1 in the same sample set. In physiological tissues, CCNA1 was only expressed at detectable levels in testis (Figure 2C).

Mapping of multiple immunogenic oligopeptides on CCNA1. For the identification of MHC class I-restricted T-cell epitopes, a reverse immunology approach was used. Four different CCNA1 mRNA variants have

30 been described that code for three different isoforms, with isoform c distinguishable by having a shorter N-terminus. As no functional domains have

been identified on the longer N-termini of isoforms a and b, and the respective transcripts for these isoforms could not be amplified by nested PCR, neither from testis nor AML samples, a peptide library representing only the shorter CCNA1 isoform c was used, so that immune escape due to targeting of epitopes in the N-termini could not occur as a consequence of cells switching CCNA1 isoforms and expressing only this shorter isoform.

After four stimulations of CD8 T-cells originating from HLA A*0201-positive donors 2196 and 2264 with the peptide library, more than 60% of cells in both T-cell lines appeared specific. Following (a) stimulation of T-cells with autologous LCL as APC pulsed with peptide pools, single 15-mers and subsequent shorter peptides, and (b) analysis of T-cell responses by intracellular staining for IFN γ , eight immunogenic oligopeptides were mapped. Donor 2196 CD8 T-cells identified immunogenic CCNA1 peptides that are identified here by the amino acid residue positions in the CCNA1 isoform c sequence:

CCNA1120-131 VDTGTLKSDLHF [SEQ ID NO:1],
CCNA1218-226 AETLYLAVN [SEQ ID NO:2],
CCNA1227-235 FLDRFLSCM [SEQ ID NO:3], and
CCNA1253-261 ASKYEEIYP [SEQ ID NO:4].

Donor 2264 CD8 T-cells identified the following immunogenic peptides from the CCNA1 isoform c polypeptide:

CCNA1118-127 YEVDGTLKS [SEQ ID NO:5],
CCNA1167-175 YAEIYQYL [SEQ ID NO:6],
CCNA1330-339 LEADPFLKYL [SEQ ID NO:7],
CCNA1341-351 SLIAAAAFCLA [SEQ ID NO:8].

Using the two normal donors to assess potential T-cell responses to CCNA1 isoform c sequences, the eight immunogenic peptides stimulated T-cells in a manner characterized by MHC restriction against at least three different HLA class I molecules. CCNA1 was expressed strictly intracellularly and epitopes from it were processed and presented in the context of Class I

MHC molecules. CCNA1 thus represented a suitable target for T-cell based therapy approaches.

T-cell clones were generated against the epitopes defined by the CCNA1 isoform c peptides 118-127 [SEQ ID NO:5], 227-235 [SEQ ID NO:3], 5 167-175 [SEQ ID NO:6], and 341-351 [SEQ ID NO:8]. Using 721.221 cells with and without stable transfected HLA A*0201 as APCs for T-cell lines in an IFN γ intracellular staining (ICS) assay, epitopes 218-226 [SEQ ID NO:2], 227-235 [SEQ ID NO:3], and 341-351 [SEQ ID NO:8] were found to be presented in a HLA A*0201-restricted manner. T-cell lines antigen-specifically directed against 10 all three epitopes could be generated using cells from both donors.

Characterization of two HLA A*0201 restricted epitopes. The 9-mer FLDRFLSCM (CCNA1227-235, [SEQ ID NO:3]) was identified as the minimal immunogenic amino acid (AA) sequence from the library peptides 56/57 that stimulated a responses as revealed from analysis of a T-cell line 15 from donor 2196 (Figure 3A). The 9-mer enhanced the stabilization of HLA A*0201 on the T2 surface when compared to the 15-mer and an irrelevant 15-mer (Figure 3 B). The IFN γ production of T-cell clones against this epitope was HLA A*0201 restricted (Figure 3 C). The 11-mer SLIAAAAFCLA (CCNA1341-351, [SEQ ID NO:8]) was identified surprisingly as the minimal 20 immunogenic AA sequence from library peptides 85/86, which stimulated a response in a T-cell line from donor 2264 (Figure 3D). Even though the 10-mer SLIAAAAFCL (10-mer 1) MHC complex was more stable than the complex with the 11-mer, only the latter was able to activate the analyzed T-cell clones (Figure 3D, 3E). The IFN γ production of T-cell clones against this epitope was 25 dependent on peptide 341-351 [SEQ ID NO:8] and HLA A*0201 expression (Figure 3F).

Cytotoxic Activity of T-cell clones specific for CCNA1 227-235 and CCNA1 341-351 against the leukemic cell line THP1. To assess a suitable 30 CCNA1 expressing leukemic cell line as a target cell, CCNA1 was quantified in five myeloid leukemia cell lines (Figure 4A). THP-1, an HLA A*0201-positive FAB M5b AML line, was found to express the highest levels of CCNA1. Clones

2196.D9, 2196.D11 and 2196.E1, which were all specific for CCNA1 227-235 [SEQ ID NO:3], were tested for reactivity against THP-1. All three clones produced IFN γ after co-incubation with autologous LCLs that had been pulsed with the peptide epitope (Figure 3C, 3F and data not shown), but only clones 5 D9 and D11 displayed significant IFN γ production in response to THP-1. These responses were enhanced by incubating the THP-1 target cells with 1000 U/ml IFN γ for 16 h before coincubation with the effectors (Figure 4B). Clone D11 showed significant lytic activity against THP-1 in a standard 6 h ^{51}Cr release assay, while the low avidity clone E1 did not (Figure 4C). Specific caspase-3 10 cleavage was observed not only for clones 2196.D9 and 2196.D11 but also for clone 2264.E30, which was directed against CCNA1341-351 [SEQ ID NO:8], indicating proper processing and presentation of both described HLA A*0201 epitopes (Figure 4C, 4D).

Recognition and Lysis of Primary AML Cells by CD8+ T-cell

15 clones specific for CCNA1 227-235. To determine if CTLs specific for a cyclin-A1 epitope recognized primary AML cells, cyclin-A1 expressing blasts from two A*0201-positive and two A*0201-negative patients were tested with clone 2196.D11_b, (“D11_b”) which recognized epitope 227-235. 2196. D11_b was first tested for induction of apoptosis in a four-hour caspase-3 assay. For maximal 20 apoptosis of these targets, staurosporine was used. As the different AML samples showed different rates of spontaneous apoptosis, the data were normalized by calculating specific caspase-3 cleavage as $100 \times (\text{experimental-spontaneous})/(\text{staurosporine-spontaneous})$. Using an E:T ratio of 5:1, 2196.D11_b induced significant apoptosis of the A*0201-positive AML 25 specimens, but not A*0201-negative ones (Figure 6A). To determine if the observed caspase-3 cleavage reflected classical lytic activity, a standard four-hour ^{51}Cr release assay was performed over a range of E:T ratios. Significant lysis of the A*0201-positive specimens was observed at an E:T as low as 1.25:1, while no specific lysis was detectable in the A*0201-negative targets. 30 Thus, primary AML cells were killed in an HLA-restricted fashion (Figure 6B).

H001 and 1690-59 were HLA A*0201 positive, and R10009 and R50400 were HLA A*0201-negative.

According to the criteria of the National Cancer Institute's list of
5 weighted "ideal" cancer antigen criteria/characteristics (Cheever et al., 2009
Clin Cancer Res 15 (17):5323- 5337), from the present disclosure CCNA1
appeared to be a highly suitable antigen for targeting AML because it was
highly expressed in AML cells including the stem cell compartment of
approximately 50% of patients, and the tissue distribution of CCNA1 expression
10 was highly restricted. Both WT1 and CCNA1 were expressed at significantly
higher levels in leukemia stem cells (LSCs) than in hematopoietic stem cells
(HSCs) (Majeti et al., 2009 *Proc Natl Acad Sci USA* 106 (9): 3396-3401).
However, unlike WT1, which was expressed in normal spleen, ovary and kidney
at levels higher than in leukemic blasts, significant CCNA1 expression was
15 found only in testis, which is generally considered an immune privileged site
(Fijak et al., 2006 *Immunol Rev* 213:66-81. doi: IMR438 [pii] 10.1111/
j.1600-065X .2006.00438.x). Consequently, cytotoxic side effects of targeting
CCNA1 appear unlikely. CCNA1 has been reported to be oncogenic in mice,
with overexpression resulting in the development of AML; CCNA1 expression
20 sustained the malignant phenotype in AML (Chan et al., 2009 *Oncogene* 28
(43):3825-3836. doi: onc 2009236 [pii] 10.1038/ onc.2009.236; Jang et al.,
2008 *Cancer Res* 68 (12):4559-4570. doi: 68/12/ 4559 [pii] 10.1158/
0008-5472.CAN- 08-0021; Ji et al., 2007 *Int J Cancer* 121 (4):706-713.
doi:10.1002 /ijc. 22634).

25 Demonstration of specific *in vitro* cytotoxicity of T-cell clones
generated against endogenously expressed and presented
malignancy-associated self-antigens has been a subject of previous reports
(Wilde et al., 2009 *Blood* 114 (10):2131-2139. doi: blood-2009- 03-209387 [pii]
10.1182/ blood-2009-03- 209387; Doubrovina et al., 2004 *Clin Cancer Res* 10
30 (21):7207-7219. doi: 10/21/ 7207 [pii] 10.1158/ 1078-0432. CCR-04- 1040;
Chaise et al., 2008 *Blood* 112 (7):2956-2964. doi: blood-2008- 02-137695 [pii]

10.1182/ blood-2008-02- 137695). Efficient cytotoxic activity of CCNA1-specific T-cell clones was observed against leukemia cells, as described herein. The level of CCNA1 expression appeared to be about one order of magnitude higher than that reported by others for WT1, the expression levels of which may oscillate as a function of the cell cycle. The CCNA1 protein is known to be regulated by the ubiquitin proteasome-mediated pathway (Ekberg et al., 2009 *Mol Cell Biochem* 320 (1-2):115- 124. doi: 10.1007/ s11010-008 -9913-3), consistent with optimal presentation of its epitopes on the surface of malignant cells.

10 Due to its role in gametogenesis, and because it appears analogous to the published classification for cancer-testis-antigens, based on the present disclosure CCNA1 is hereby classified as a leukemia-testis-antigen of the non-X type (Simpson et al., 2005 *Nat Rev Cancer* 5 (8):615-625. doi: nrc1669 [pii] 10.1038/ nrc1669). CCNA1 was expressed in LSCs and as disclosed herein appears to be the first described non-X leukemia-testis-antigen. The tissue-selective expression pattern of CCNA1, its high expression levels in AML, its function in oncogenesis, and the multitude of CCNA1 immunogenic T-cell epitopes described herein make CCNA1 an optimal target for T-cell based therapeutic approaches including those described herein, and also including vaccination and/or adoptive T-cell transfer.

Additional References: Yang et al., 2010 *Cell Oncol* 32 (1-2):131-143. doi: G7V87116 LNJ27 053 [pii] 10.3233/ CLO-2009-0510; Brait et al., 2008 *Cancer Epidemiol Biomarkers Prev* 17 (10): 2786-2794. doi:17/ 10/2786 [pii] 10.1158/ 1055-9965. EPI-08-0192; Spisak et al., 2010 *Dis Markers* 28 (1):1-14. doi: K32K0082 1215536H [pii] 10.3233/ DMA-2010- 0677; Farhadieh et al., 2009 *ANZ J Surg* 79 (1-2):48-54. doi: ANS4799 [pii] 10.1111/ j.1445-2197. 2008. 04799.x; Wegiel et al., 2008 *J Natl Cancer Inst* 100 (14):1022-1036. doi: djn214 [pii] 10.1093/ jnci/djn214; Coletta et al., 2008 *Cancer Res* 68 (7):2204-2213. doi: 68/7/ 2204 [pii] 10.1158/ 0008-5472. CAN-07-3141; Cho et al., 2006 *Cancer Sci* 97 (10):1082-1092. doi: CAS292

[pii] 10.1111/j.1349-7006.2006.00292.x; Fijak et al., 2006 *Immunol Rev* 213:66-81. doi: IMR438 [pii] 10.1111/j.1600-065X.2006.00438.x; Rammensee et al., 1999 *Immunogenetics* 50 (3-4):213-219. doi:90500213.251 [pii]; Lundegaard et al., 2008 *Nucleic Acids Res* 36 (Web Server issue):W509-512. doi:gkn202 [pii] 10.1093/nar/gkn202.

The various embodiments described above can be combined to provide further embodiments. All of the U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification and/or listed in the Application Data Sheet are incorporated herein by reference, in their entirety. Aspects of the embodiments can be modified, if necessary to employ concepts of the various patents, applications and publications to provide yet further embodiments.

These and other changes can be made to the embodiments in light of the above-detailed description. In general, in the following claims, the terms used should not be construed to limit the claims to the specific embodiments disclosed in the specification and the claims, but should be construed to include all possible embodiments along with the full scope of equivalents to which such claims are entitled. Accordingly, the claims are not limited by the disclosure.

Equivalents

While particular steps, elements, embodiments and applications of the present invention have been shown and described herein for purposes of illustration, it will be understood, of course, that the invention is not limited thereto since modifications may be made by persons skilled in the art, particularly in light of the foregoing teachings, without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

CLAIMS

What is claimed is:

1. An isolated peptide capable of eliciting an antigen-specific T-cell response to human cyclin A1 (CCNA1), comprising a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8 or 7 amino acids wherein the polypeptide comprises a sequence of at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 contiguous amino acids from the CCNA1 amino acid sequence set forth in SEQ ID NO:9.

2. An isolated peptide capable of eliciting an antigen-specific T-cell response to human cyclin A1 (CCNA1), comprising a polypeptide of general formula I:

N-X-C, [I]

wherein:

(a) N-X-C is a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10 or 9 amino acids in which X comprises an amino acid sequence that is selected from:

CCNA1(120-131) VDTGTLKSDLHF	[SEQ ID NO:1],
CCNA1(218-226) AETLYLAVN	[SEQ ID NO:2],
CCNA1(227-235) FLDRFLSCM	[SEQ ID NO:3],
CCNA1(253-261) ASKYEEIYP	[SEQ ID NO:4],
CCNA1(118-127) YEVDGTLKS	[SEQ ID NO:5],
CCNA1(167-175) YAEIYQYL	[SEQ ID NO:6],
CCNA1(330-339) LEADPFLKYL	[SEQ ID NO:7], and
CCNA1(341-351) SLIAAAAFCLA	[SEQ IN NO:8],

(b) N is an amino terminus of the peptide and consists of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino acids that are independently selected from natural amino acids and non-natural amino acids, and

(c) C is a carboxy terminus of the peptide and consists of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino acids that are independently selected from natural amino acids and non-natural amino acids.

3. The isolated peptide of either claim 1 or claim 2 wherein the antigen-specific T-cell response comprises major histocompatibility complex (MHC)-restricted T-cell recognition of the peptide.

4. The isolated peptide of either claim 1 or claim 2 which is capable of eliciting an antigen-specific CD8⁺ T-cell response to human cyclin A1 (CCNA1) in a class I human leukocyte antigen (HLA)-restricted manner.

5. The isolated peptide of claim 4 wherein the class I HLA antigen is HLA-A*201.

6. The isolated peptide of either claim 1 or claim 2 which is capable of eliciting an antigen-specific CD4⁺ T-cell response to human cyclin A1 (CCNA1) in a class II human leukocyte antigen (HLA)-restricted manner.

7. The isolated peptide of either claim 1 or claim 2 wherein the antigen-specific T-cell response comprises an interferon-gamma (IFN- γ) response.

8. The isolated peptide of either claim 1 or claim 2 wherein the antigen-specific T-cell response comprises at least one of a CD4⁺ helper T lymphocyte (Th) response and a CD8⁺ cytotoxic T lymphocyte (CTL) response.

9. The isolated peptide of claim 8 wherein the CTL response is directed against a CCNA1-overexpressing cell.

10. The isolated peptide of claim 9 wherein the CCNA1-overexpressing cell is an acute myeloid leukemia (AML) cell or a leukemic stem cell (LSC).

11. An isolated polynucleotide that encodes a peptide that is capable of eliciting an antigen-specific T-cell response to human cyclin A1 (CCNA1), the peptide comprising a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8 or 7 amino acids wherein the polypeptide comprises a sequence of at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 contiguous amino acids from the CCNA1 amino acid sequence set forth in SEQ ID NO:9.

12. An isolated polynucleotide that encodes a peptide that is capable of eliciting an antigen-specific T-cell response to human cyclin A1 (CCNA1), the peptide comprising a polypeptide of general formula I:

N-X-C, [I]

wherein:

(a) N-X-C is a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10 or 9 amino acids in which X comprises an amino acid sequence that is selected from:

CCNA1(120-131) VDTGTLKSDLHF	[SEQ ID NO:1],
CCNA1(218-226) AETLYLAVN	[SEQ ID NO:2],
CCNA1(227-235) FLDRFLSCM	[SEQ ID NO:3],
CCNA1(253-261) ASKYEEIYP	[SEQ ID NO:4],
CCNA1(118-127) YEVDGTGLKS	[SEQ ID NO:5],
CCNA1(167-175) YAEIYQYL	[SEQ ID NO:6],
CCNA1(330-339) LEADPFLKYL	[SEQ ID NO:7], and
CCNA1(341-351) SLIAAAAFCLA	[SEQ IN NO:8],

(b) N is an amino terminus of the peptide and consists of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino acids that are independently selected from natural amino acids and non-natural amino acids, and

(c) C is a carboxy terminus of the peptide and consists of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino acids that are independently selected from natural amino acids and non-natural amino acids.

13. An immunogenic composition comprising a recombinant expression vector comprising the polynucleotide of either claim 11 or claim 12 operably linked to an expression control sequence.

14. The immunogenic composition of claim 13 wherein the vector is capable of delivering the polynucleotide to an antigen-presenting cell.

15. The immunogenic composition of claim 14 wherein the antigen-presenting cell is a dendritic cell.

16. The immunogenic composition of claim 13 wherein the antigen-specific T-cell response comprises major histocompatibility complex (MHC)-restricted T-cell recognition of the peptide.

17. The immunogenic composition of claim 13 which is capable of eliciting an antigen-specific CD8⁺ T-cell response to human cyclin A1 (CCNA1) in a class I human leukocyte antigen (HLA)-restricted manner.

18. The immunogenic composition of claim 17 wherein the class I HLA antigen is HLA-A*201.

19. The immunogenic composition of claim 13 which is capable of eliciting an antigen-specific CD4⁺ T-cell response to human cyclin A1 (CCNA1) in a class II human leukocyte antigen (HLA)-restricted manner.

20. The immunogenic composition of claim 13 wherein the antigen-specific T-cell response comprises an interferon-gamma (IFN- γ) response.
21. The immunogenic composition of claim 13 wherein the antigen-specific T-cell response comprises at least one of a CD4⁺ helper T lymphocyte (Th) response and a CD8⁺ cytotoxic T lymphocyte (CTL) response.
22. The immunogenic composition of claim 21 wherein the CTL response is directed against a CCNA1-overexpressing cell.
23. The immunogenic composition of claim 22 wherein the CCNA1-overexpressing cell is an acute myeloid leukemia (AML) cell or a leukemic stem cell (LSC).
24. A method of treating a condition characterized by CCNA1 overexpression in cells of a subject, comprising administering to the subject an effective amount of a composition that comprises one or more isolated peptides that are capable of eliciting an antigen-specific T-cell response to human cyclin A1 (CCNA1), each of said isolated peptides comprising a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8 or 7 amino acids wherein the polypeptide comprises a sequence of at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 contiguous amino acids from the CCNA1 amino acid sequence set forth in SEQ ID NO:9.
25. A method of treating a condition characterized by CCNA1 overexpression in cells of a subject, comprising administering to the subject an effective amount of a composition that comprises one or more isolated peptides that are capable of eliciting an antigen-specific T-cell response to human cyclin A1 (CCNA1), each of said isolated peptides comprising a polypeptide of general formula I:

N-X-C, [I]

wherein:

(a) N-X-C is a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10 or 9 amino acids in which X comprises an amino acid sequence that is selected from:

CCNA1(120-131) VDTGTLKSDLHF	[SEQ ID NO:1],
CCNA1(218-226) AETLYLAVN	[SEQ ID NO:2],
CCNA1(227-235) FLDRFLSCM	[SEQ ID NO:3],
CCNA1(253-261) ASKYEEIYP	[SEQ ID NO:4],
CCNA1(118-127) YEVDGTGLKS	[SEQ ID NO:5],
CCNA1(167-175) YAEIYQYL	[SEQ ID NO:6],
CCNA1(330-339) LEADPFLKYL	[SEQ ID NO:7], and
CCNA1(341-351) SLIAAAAFCLA	[SEQ IN NO:8],

(b) N is an amino terminus of the peptide and consists of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino acids that are independently selected from natural amino acids and non-natural amino acids, and

(c) C is a carboxy terminus of the peptide and consists of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino acids that are independently selected from natural amino acids and non-natural amino acids.

26. A method of treating a condition characterized by CCNA1 overexpression in cells of a subject, comprising administering to the subject an effective amount of a composition that comprises one or more isolated polynucleotides that each encodes a peptide that is capable of eliciting an antigen-specific T-cell response to human cyclin A1 (CCNA1), each of said peptides comprising a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8 or 7 amino acids wherein the polypeptide comprises a sequence of at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 contiguous amino acids from the CCNA1 amino acid sequence set forth in SEQ ID NO:9.

27. A method of treating a condition characterized by CCNA1 overexpression in cells of a subject, comprising administering to the subject an effective amount of a composition that comprises one or more isolated polynucleotides that each encodes a peptide that is capable of eliciting an antigen-specific T-cell response to human cyclin A1 (CCNA1), each of said peptides comprising a polypeptide of general formula I:

N-X-C, [I]

wherein:

(a) N-X-C is a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10 or 9 amino acids in which X comprises an amino acid sequence that is selected from:

CCNA1(120-131) VDTGTLKSDLHF	[SEQ ID NO:1],
CCNA1(218-226) AETLYLAVN	[SEQ ID NO:2],
CCNA1(227-235) FLDRFLSCM	[SEQ ID NO:3],
CCNA1(253-261) ASKYEEIYP	[SEQ ID NO:4],
CCNA1(118-127) YEVDGTLKS	[SEQ ID NO:5],
CCNA1(167-175) YAEIYQYL	[SEQ ID NO:6],
CCNA1(330-339) LEADPFLKYL	[SEQ ID NO:7], and
CCNA1(341-351) SLIAAAAFCLA	[SEQ IN NO:8],

(b) N is an amino terminus of the peptide and consists of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino acids that are independently selected from natural amino acids and non-natural amino acids, and

(c) C is a carboxy terminus of the peptide and consists of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino acids that are independently selected from natural amino acids and non-natural amino acids.

28. The method of either claim 26 or claim 27 wherein the step of administering comprises administering an immunogenic composition comprising one or more recombinant expression vectors that comprise the one or more isolated polynucleotides, each of said isolated polynucleotide being operably linked to an expression control sequence.

29. The method of claim 28 wherein the vector is capable of delivering the polynucleotide to an antigen-presenting cell.

30. The method of claim 29 wherein the antigen-presenting cell is a dendritic cell.

31. The method of any one of claims 24-27 wherein the condition characterized by CCNA1 overexpression is a leukemia.

32. The method of claim 31 wherein the leukemia is acute myeloid leukemia.

33. A method for treating a condition characterized by CCNA1 overexpression in cells of a subject, comprising:

(A) contacting in vitro, under conditions and for a time sufficient for antigen processing and presentation by antigen-presenting cells to take place, (i) a population of antigen-presenting cells that are immunocompatible with the subject, and (ii) an isolated peptide capable of eliciting an antigen-specific T-cell response to human cyclin A1 (CCNA1), comprising a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8 or 7 amino acids wherein the polypeptide comprises a sequence of at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 contiguous amino acids from the CCNA1 amino acid sequence set forth in SEQ ID NO:9; and

(B) administering one or a plurality of said antigen-pulsed antigen-presenting cells to the subject in an amount effective to elicit said antigen-specific T-cell response to human cyclin A1 (CCNA1).

34. A method for treating a condition characterized by CCNA1 overexpression in cells of a subject, comprising:

(A) contacting in vitro, under conditions and for a time sufficient for antigen processing and presentation by antigen-presenting cells to

take place, (i) a population of antigen-presenting cells that are immunocompatible with the subject, and (ii) an isolated peptide capable of eliciting an antigen-specific T-cell response to human cyclin A1 (CCNA1), comprising a polypeptide of general formula I:

N-X-C, [I]

wherein:

(a) N-X-C is a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10 or 9 amino acids in which X comprises an amino acid sequence that is selected from:

CCNA1(120-131) VDTGTLKSDLHF	[SEQ ID NO:1],
CCNA1(218-226) AETLYLAVN	[SEQ ID NO:2],
CCNA1(227-235) FLDRFLSCM	[SEQ ID NO:3],
CCNA1(253-261) ASKYEEIYP	[SEQ ID NO:4],
CCNA1(118-127) YEVDGTLKS	[SEQ ID NO:5],
CCNA1(167-175) YAEIYQYL	[SEQ ID NO:6],
CCNA1(330-339) LEADPFLKYL	[SEQ ID NO:7], and
CCNA1(341-351) SLIAAAAFCLA	[SEQ IN NO:8],

(b) N is an amino terminus of the peptide and consists of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino acids that are independently selected from natural amino acids and non-natural amino acids, and

(c) C is a carboxy terminus of the peptide and consists of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino acids that are independently selected from natural amino acids and non-natural amino acids, and thereby obtaining a population of antigen-pulsed antigen-presenting cells; and

(B) administering one or a plurality of said antigen-pulsed antigen-presenting cells to the subject in an amount effective to elicit said antigen-specific T-cell response to human cyclin A1 (CCNA1).

35. A method for treating a condition characterized by CCNA1 overexpression in cells of a subject, comprising:

(A) contacting in vitro, under conditions and for a time sufficient for antigen processing and presentation by antigen-presenting cells to take place, (i) a population of antigen-presenting cells that are immunocompatible with the subject, and (ii) a composition that comprises an isolated polynucleotide that can be expressed by said antigen-presenting cells and that encodes a peptide that is capable of eliciting an antigen-specific T-cell response to human cyclin A1 (CCNA1), the peptide comprising a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8 or 7 amino acids wherein the polypeptide comprises a sequence of at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 contiguous amino acids from the CCNA1 amino acid sequence set forth in SEQ ID NO:9; and

(B) administering one or a plurality of said antigen-pulsed antigen-presenting cells to the subject in an amount effective to elicit said antigen-specific T-cell response to human cyclin A1 (CCNA1).

36. A method for treating a condition characterized by CCNA1 overexpression in cells of a subject, comprising:

(A) contacting in vitro, under conditions and for a time sufficient for antigen processing and presentation by antigen-presenting cells to take place, (i) a population of antigen-presenting cells that are immunocompatible with the subject, and (ii) a composition that comprises an isolated polynucleotide that can be expressed by said antigen-presenting cells and that encodes a peptide that is capable of eliciting an antigen-specific T-cell response to human cyclin A1 (CCNA1), the peptide comprising a polypeptide of general formula I:

N-X-C, [I]

wherein:

(a) N-X-C is a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10 or 9 amino acids in which X comprises an amino acid sequence that is selected from:

CCNA1(120-131) VDTGTLKSDLHF	[SEQ ID NO:1],
CCNA1(218-226) AETLYLAVN	[SEQ ID NO:2],
CCNA1(227-235) FLDRFLSCM	[SEQ ID NO:3],
CCNA1(253-261) ASKYEEIYP	[SEQ ID NO:4],
CCNA1(118-127) YEVDGTLKS	[SEQ ID NO:5],
CCNA1(167-175) YAEIYQYL	[SEQ ID NO:6],
CCNA1(330-339) LEADPFLKYL	[SEQ ID NO:7], and
CCNA1(341-351) SLIAAAAFCLA	[SEQ IN NO:8],

(b) N is an amino terminus of the peptide and consists of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino acids that are independently selected from natural amino acids and non-natural amino acids, and

(c) C is a carboxy terminus of the peptide and consists of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino acids that are independently selected from natural amino acids and non-natural amino acids, and thereby obtaining a population of antigen-pulsed antigen-presenting cells; and

(B) administering one or a plurality of said antigen-pulsed antigen-presenting cells to the subject in an amount effective to elicit said antigen-specific T-cell response to human cyclin A1 (CCNA1).

37. The method of any one of claims 33-36 which further comprises a step of expanding the number of antigen-presenting cells by culturing the antigen-presenting cells after the step of contacting and prior to the step of administering.

38. The method of any one of claims 33-36 which further comprises:

(C) (1) contacting the antigen-pulsed antigen-presenting cells with one or a plurality of immunocompatible T-cells after step (A), under conditions and for a time sufficient to generate CCNA1-specific T-cells, and
(2) adoptively transferring the CCNA1-specific T-cells to the subject.

39. The method of claim 38 in which step (B) is omitted.

40. The method of any one of claims 33-36 which further comprises:

(C) (1) contacting the antigen-pulsed antigen-presenting cells with one or a plurality of immunocompatible T-cells after step (A), under conditions and for a time sufficient to generate CCNA1-specific T-cells,

(2) expanding the CCNA1-specific T-cells to obtain one or more clones of said CCNA1-specific T-cells in amounts sufficient for T-cell receptor structural characterization,

(3) determining a T-cell receptor polypeptide encoding nucleic acid sequence for one or more of said CCNA1-specific T-cells,

(4) transfecting an adoptive transfer T-cell population with at least one T-cell receptor polypeptide encoding nucleic acid having a sequence determined in (3) to obtain engineered CCNA1-specific adoptive transfer T-cells,

and

4) adoptively transferring the engineered CCNA1-specific adoptive transfer T-cells to the subject.

41. The method of claim 40 in which step (B) is omitted.







Fig. 1

Epitope CCNA1₂₂₇₋₂₃₅



Epitope CCNA1₃₄₁₋₃₅₁





Fig. 3




Fig. 4

Human Cyclin A1 Isoform c

NCBI reference sequence NP_001104517.1 GI:161377472

Polypeptide Sequence:

```
1   mhcsnpksgv vlatvargpd acqiltrapl gqppqrtvl gltangqyr rtcgqgitri
61  rcysgsenaf ppagkkalpd cgveppkqg fdiymdeleq gdrdscsvre gmafedvyev
121 dtgtlksdlh flldfntvsp mlvdssllsq sedisslgtv vinvteyae iyqylreaei
181 rhrpkahymk kqpditegmr tilvdwlvev geeykraet lylavnfldr flscmsvlrg
241 klqlvgtaam llaskyeeiy ppevdefvyi tddtytkrql lkmehlilkv lafdltvptt
301 nqfllqylrr qgvcvrtenl akyvaelsll eadpflkylp sliaaaafcl anytvnkhfw
361 petlaaftgy slseivpcls elhkayldip hrpqqairek ykaskylcvs lmeppavlll
421 q      [SEQ ID NO:9]
```

Fig. 5A

NCBI Reference sequence NM_001111047.1 GI:161377471 Polynucleotide Sequence:

```
1 gccgcagcct gccgcagccc gaggaccccg cgtcgcctctc ccgagccagg gttctcagga
61 gcggggccgcg caggagacgt tagaggggggt tgtagcggc tgtagggaga acgggtcacg
121 gaaacagtcc ctcccaaagc cggggccatc gtgggggtgg cgagtcgcc ctcccaggcc
181 gggggcgcgg accagagggg acgtgtgcag acggccgcgg tcagccccac ctgcccggg
241 cggagacgca cagctggagc tggagggccg tcgcccttg gccctcagg ggccctgaacg
301 cccaggggtc gcggcgagtc caccggagc gagtcagcag cccgtggagt ctgaagcaat
361 gcaactgcagc aacccaaga gtggagttgt gctggctaca gtggcccagag gtcccgatgc
421 ttgtcagata ctaccagag cccgcctggg ccaggatccc ccgagagga cagtgttagg
481 gctgctaact gcaaatgggc agtacaggag gacctgtggc caggggatca caagaatcag
541 gtgttattct ggatcagaaa atgccttccc tccagctgga aagaaagcac tcctgactg
601 tgggggtcaa gagccccca agcaagggtt tgacatctac atggatgaac tagagcaggg
661 ggacagagac agctgctcgg tcagagaggg gatggcattt gaggatgtgt atgaagtaga
721 caccggcaca ctcaagtcag acctgcactt cctgctggat ttcaacacag tttcccctat
781 gctggtagat tcatctctcc tctcccagtc tgaagatata tccagtcttg gcacagatgt
841 gataaatgtg actgaatatg ctgaagaaat ttatcagtac cttaggggaag ctgaataag
901 gcacagaccc aaagcacact acatgaagaa gcagccagac atcacggaag gcatgcgcac
961 gattctgggtg gactggctgg tggaggttgg ggaagaatat aaacttcgag cagagaccct
1021 gtatctgggt gtcaacttcc tggacagggt ctttctatgt atgtctgttc tgagagggaa
1081 actgcagctc gtaggaacag cagctatget tttggcttcg aaatatgaag agatataatcc
1141 tcctgaagta gacgagtttg tctatatcac cgatgataca tacacaaaac gacaactggt
1201 aaaaatggaa cacttgcttc tgaaagttct agcttttgat ctgacagtac caaccacaa
1261 ccagtttctc cttcagtact tgaggcgaca aggagtgtgc gtcaggactg agaacctggc
1321 taagtacgta gcagagctga gtctacttga agcagatcca ttcttgaaat atcttccctc
1381 actgatagct gcagcagctt tttgcctggc aaactatact gtgaacaagc acttttggcc
1441 agaaaccctt gctgcattta cagggtattc attaagtga atgtgtcctt gcctgagtga
1501 gcttcataaa gcgtaccttg atatacccca tcgacctcag caagcaatta gggagaagta
1561 caaggcttca aagtacctgt gtgtgtccct catggagcca cctgcagttc ttcttctaca
1621 ataagtttct gaatggaagc acttccagaa cttcacctcc atatcagaag tgccaataat
1681 cgtcataggc ttctgcacgt tggatcaact aatggtggtt acaatataga tgacatttta
1741 aaaatgtaa tgaatttagt ttcccttaga ctttagtagt ttgtaataata gtccaacatt
1801 ttttaacaa taaactgctt gtcttatgac catgtgtag a
```

Fig. 5B

/translation=
"MHCSNPKSGVVLATVARGPDACQILTRAPLGQDPPQRTVLGLLT
ANGQYRRTCQGGITRIRCYSGSENAFPPAGKKALPDCGVQEPPKQGFDIYMDELEQGD
RDSCSVREGMAFEDVYEVDTGTLKSDLHFLLDNFNTVSPMLVDSSLLSQSEDISSLGTD
VINVTEYAEEIYQYLREAEIRHRPKAHYMKKQPDITEGMRTILVDWLVEVGEEYKLRA
ETLYLAVNFLDRFLSCMSVLRGKLQLVGTAAMLLASKYEIYPPEVDEFVYITDDTYT
KRQLLKMEHLLLKVLAFDLTVPTTNQFLLQYLRRQGV CVRTENLAKYVAELSLEADP
FLKYLPSLIAAAAFCLANYTVNKHFWPETLAAFTGYSLSEIVPCLSELHKAYLDIPHR
PQQAIREKYKASKYLCVSLMEPPAVLLLQ [SEQ ID NO:10]

Fig. 5B (cont'd)




Fig. 6

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2012/064511**A. CLASSIFICATION OF SUBJECT MATTER***C07K 7/06(2006.01)i, C07K 7/08(2006.01)i, C12N 15/12(2006.01)i, C12N 5/10(2006.01)i, A61K 38/08(2006.01)i, A61K 38/10(2006.01)i, A61P 35/00(2006.01)i*

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07K 7/06; A61K 39/395; C12N 15/63; C07H 21/04; C07K 16/18; A01K 67/027

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Korean utility models and applications for utility models
Japanese utility models and applications for utility models

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

eKOMPASS(KIPO internal) & Keywords: cyclin A1, CCNA1, T-cell response, immunogenic composition, CD8+, CD4+, acute myeloid leukemia(AML) cell, leukemic stem cell

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2010-0047239 A1 (WU, CHENGBIN et al.) 25 February 2010 See claims 21-24.	1-23
A	LELE, KAREN, M. et al., 'Distinct regions of the mouse cyclin A1 gene, CenA1, confer male germ-cell specific expression and enhancer function', Biology of Reproduction, 23 June 2004, Vol. 71, No. 4, pp. 1340-1347. See abstract; page 1346.	1-23
A	US 2011-0236375 A1 (LAZAR, GREGORY A. et al.) 29 September 2011 See claims 1 and 15; paragraph [0135].	1-23
A	US 2002-0053092 A1 (READHEAD, CAROL W. et al.) 2 May 2002 See claims 1 and 4.	1-23
PX	OCHSENREITHER, SEBASTIAN et al., 'Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen', Blood, 23 April 2012, Vol. 119, No. 2, pp. 5492-5501. See whole document.	1-23

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

27 March 2013 (27.03.2013)

Date of mailing of the international search report

29 March 2013 (29.03.2013)

Name and mailing address of the ISA/KR

Korean Intellectual Property Office
189 Cheongsu-ro, Seo-gu, Daejeon Metropolitan
City, 302-701, Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

HEO, Joo Hyung

Telephone No. 82-42-481-8150



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2012/064511**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 24-41
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 24-41 pertain to methods for treatment of the human body by therapy, and thus relate to a subject matter which this International Searching Authority is not required, under Article 17(2)(a)(i) of the PCT and Rule 39.1(iv) of the Regulations under the PCT, to search.
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2012/064511

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2010-0047239 A1	25.02.2010	EP 2056869 A2	13.05.2009
		EP 2056869 A4	21.10.2009
		EP 2495257 A2	05.09.2012
		EP 2495257 A3	17.10.2012
		EP 2500352 A1	19.09.2012
		EP 2500353 A2	19.09.2012
		EP 2500353 A3	10.10.2012
		EP 2500354 A2	19.09.2012
		EP 2500354 A3	24.10.2012
		EP 2500355 A2	19.09.2012
		EP 2500355 A3	24.10.2012
		EP 2500356 A2	19.09.2012
		EP 2500356 A3	24.10.2012
		EP 2500357 A2	19.09.2012
		EP 2500357 A3	24.10.2012
		EP 2500358 A2	19.09.2012
		EP 2500358 A3	17.10.2012
		EP 2500359 A2	19.09.2012
		EP 2500359 A3	17.10.2012
		TW 1323734 A	21.04.2010
		US 2007-0071675 A1	29.03.2007
		US 2009-0215992 A1	27.08.2009
		US 7612181 B2	03.11.2009
		US 8258268 B2	04.09.2012
		WO 2008-024188 A2	28.02.2008
		WO 2008-024188 A3	04.09.2008
		WO 2008-024188 A8	03.07.2008
US 2011-0236375 A1	29.09.2011	WO 2011-091078 A2	28.07.2011
		WO 2011-091078 A3	01.12.2011
		WO 2011-091078 A9	19.01.2012
US 2002-0053092 A1	02.05.2002	AU 1999-14061 A1	07.06.1999
		AU 1999-14061 B2	12.06.2003
		AU 1999-35634 A1	05.06.2000
		AU 1999-40771 A1	05.06.2000
		AU 2000-52688 A1	05.12.2000
		AU 2000-52688 B2	28.04.2005
		CA 2309904 A1	27.05.1999
		CA 2350829 A1	25.05.2000
		CA 2368620 A1	23.11.2000
		EP 1030929 A1	30.08.2000
		EP 1030929 B1	18.03.2009
		EP 1047792 A1	02.11.2000
		EP 1129205 A1	05.09.2001
		EP 1190086 A2	27.03.2002
		JP 2001-523468 A	27.11.2001
		JP 2002-543814 A	24.12.2002
		JP 2003-525581 A	02.09.2003

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2012/064511

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		JP 2003-526326 A	09.09.2003
		US 2002-0056148 A1	09.05.2002
		US 2002-0083479 A1	27.06.2002
		US 2002-0129398 A1	12.09.2002
		US 2002-0133835 A1	19.09.2002
		US 2002-0138865 A1	26.09.2002
		US 2005-0034177 A1	10.02.2005
		US 2008-0178311 A1	24.07.2008
		US 6316692 B1	13.11.2001
		US 6734338 B1	11.05.2004
		US 7294755 B1	13.11.2007
		WO 00-29601 A1	25.05.2000
		WO 00-29602 A1	25.05.2000
		WO 00-69257 A2	23.11.2000
		WO 99-25863 A1	27.05.1999